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2 C.-E. Chiang et al. / Journal of the Chinese Medical Association 78 (2015) 1e47have been loosened in high risk patients. The Executive Board members of TSOC and the Taiwan Hypertension Society (THS) aimed to review
updated information about the management of hypertension to publish an updated hypertension guideline in Taiwan.
We recognized that hypertension is the most important risk factor for global disease burden. Management of hypertension is especially
important in Asia where the prevalence rate grows faster than other parts of the world. In most countries in East Asia, stroke surpassed coronary
heart disease (CHD) in causing premature death. A diagnostic algorithm was proposed, emphasizing the importance of home BP monitoring and
ambulatory BP monitoring for better detection of night time hypertension, early morning hypertension, white-coat hypertension, and masked
hypertension. We disagreed with the ESH/ESH joint hypertension guidelines suggestion to loosen BP targets to <140/90 mmHg for all patients. We
strongly disagree with the suggestion by the 2014 JNC report to raise the BP target to <150/90 mmHg for patients between 60-80 years of age. For
patients with diabetes, CHD, chronic kidney disease who have proteinuria, and those who are receiving antithrombotic therapy for stroke pre-
vention, we propose BP targets of <130/80 mmHg in our guidelines. BP targets are <140/90 mmHg for all other patient groups, except for patients
80 years of age in whom a BP target of <150/90 mmHg would be optimal.
For themanagement of hypertension, we proposed a treatment algorithm, startingwith life stylemodification (LSM) includingS-ABCDE (Sodium
restriction,Alcohol limitation,Bodyweight reduction,Cigarette smoke cessation,Diet adaptation, andExercise adoption). We emphasized a low-salt
strategy instead of a no-salt strategy, and that excessively aggressive sodium restriction to <2.0 gram/day may be harmful. When drug therapy is
considered, a strategy called “PROCEED” was suggested (Previous experience, Risk factors, Organ damage, Contraindications or unfavorable
conditions, Expert's or doctor's judgment, Expenses or cost, andDelivery and compliance issue). To predict drug effects in lowering BP, we proposed
the “Rule of 10” and “Rule of 5”.With a standard dose of any one of the 5major classes of anti-hypertensive agents, one can anticipate approximately a
10-mmHg decrease in systolic BP (SBP) (Rule of 10) and a 5-mmHg decrease in diastolic BP (DBP) (Rule of 5). When doses of the same drug are
doubled, there is only a 2-mmHg incremental decrease in SBP and a 1-mmHg incremental decrease in DBP. Preferably, when 2 drugs with different
mechanisms are to be taken together, the decrease in BP is the sum of the decrease of the individual agents (approximately 20 mmHg in SBP and
10 mmHg in DBP). Early combination therapy, especially single-pill combination (SPC), is recommended.
When patient's initial treatment cannot get BP to targeted goals, we have proposed an adjustment algorithm, “ATGOALs” (Adherence,Timing of
administration, Greater doses,Other classes of drugs, Alternative combination or SPC, and LSM þ Laboratory tests). Treatment of hypertension in
special conditions, including treatment of resistant hypertension, hypertension in women, and perioperative management of hypertension, were also
mentioned.
The TSOC/THS hypertension guidelines provide the most updated information available in the management of hypertension. The guidelines are
not mandatory, and members of the task force fully realize that treatment of hypertension should be individualized to address each patient's cir-
cumstances. Ultimately, the decision of the physician decision remains of the utmost importance in hypertension management.
Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Advisory board meetings for 2015 TSOC/THS hypertension
guidelines.
Time Location
May 11, 2013, AM Taichung
May 11, 2013, PM Taipei
May 25, 2013, AM Taipei
May 25, 2013, PM Taichung
July 27, 2013, AM Kaohsiung
July 27, 2013, PM Taichung
November 10, 2013, AM Tainan
November 24, 2013, PM Taipei
THS ¼ Taiwan Hypertension Society; TSOC ¼ Taiwan Soci-
ety of Cardiology.High blood pressure (BP) is the most important risk factor
for global disease burden.1, 2 Among the 25 leading risk
factors for global DALYs (Disability-Adjusted Life-Years),
high BP was ranked number 4 in 1990, but moved up to
number 1 in 2010.3 The number of deaths attributable to high
BP rose from 7.2 million in 1990 to 9.4 million in 2010.2
Appromimately 54% of stroke and 47% of coronary heart
disease (CHD) worldwide were attributable to high BP.4
Hypertension is also a very common disease, in fact, the
life time risk of having hypertension is about 90%.5 Addi-
tionally, it has been noted that the prevalence rate of hyper-
tension is rapidly growing. There was 972 million patients
with hypertension (26.4%) in 2000 and that number will
reach 1.56 billion (29.2%) in 2025, an alarmingly 60% in-
crease in just 25 years.6
Despite being a major risk factor for cardiovascular
morbidity and mortality, the control rate of hypertension is
generally low. Except for in the United States, the control rate
for hypertension in most countries is generally below 50%.7
For instance, the control rate in 2009 was 32.0% in England,
and 24.8% in Japan.7 In a survey in 2002 in Taiwan, the
control rate was only 21% in men, and 29% in women.8
The Taiwan Society of Cardiology (TSOC) has previously
published its 2010 guidelines for the management of hyper-
tension.9 More recently, the European Society of Hypertension
(ESH) and the European Society of Cardiology (ESC) have
published their joint hypertension guidelines in 2013.10 The
panel members who were appointed to the Eighth Joint Na-
tional Committee (JNC) also published the 2014 JNC report.11
Based on some new data from clinical trials, post-hoc ana-
lyses, and meta-analyses, the Executive Board Members of
TSOC and the Taiwan Hypertension Society (THS) decided to
publish an updated hypertension guidelines in Taiwan.1.1. How were the guidelines created?The Executive Board of TSOC appointed a chairperson to
nominate a task force of 15 members, based on their expertise,
from both TSOC and THS. Each member was assigned a
specific writing task. Systemic review was performed by
searching for all available evidences, including randomized
controlled trials (RCTs), non-randomized trials, post-hoc an-
alyses, subgroup analyses, retrospective studies, cohort
studies, and registries. Eight face-to-face advisory board
meetings have been held in 2013 (Table 1). In these meetings,
members of the task force gave presentations, and were joined
by other advisory board members (38 experts in total) for
detailed discussions. All the presentations were recorded and
could be viewed on line (http://tw.i519.org/tsoc). Thereafter,
the text was finalized over a period of 6 months.
The task force uses evidence-based methodologies similar
to those developed by the American College of Cardiology
(ACC) and the American Heart Association (AHA).12 The
Class of Recommendation (COR) is an estimate of the size of
the treatment effect, with consideration given to risks versusbenefits, as well as evidence and/or agreement that a given
treatment or procedure is or is not useful/effective or in some
situations may be harmful (Table 2). The Level of Evidence
(LOE) is an estimate of the certainty or precision of the
treatment effect. The task force reviewed and ranked evidence
supporting each recommendation, with the weight of evidence
ranked as LOE A, B, or C, according to specific definitions
that are included in Table 3.1.2. Comparison of hypertension guidelinesSimilarities and differences between the 2013 ESH/ESC
hypertension guidelines,10 the 2014 JNC report,11 and the
present TSOC/TSH hypertension guidelines were shown in
Table 4. The most important differences are the BP targets.
The rationale of BP targets in the present TSOC/THS hyper-
tension guidelines were discussed in other parts of this paper
(Section 6.2 to Section 6.9). To make the guidelines simple,
we did not cover treatment of associated risk factors-such as
high cholesterol or elevated blood sugar. In general, each of
these 3 hypertension guidelines fulfilled the standards for
guideline formation, suggested by the Institute of Medicine
(IOM).13 The present TSOC/THS hypertension guidelines
emphasized the importance of stroke when considering the
cardiovascular endpoints, making it more Asian-oriented.
2. Epidemiology2.1. Hypertension in AsiaThe age-adjusted prevalence rate of hypertension is around
20e30% in Asian countries,8, 14 similar to that in developed
countries in the Western world.6 However, the expected in-
crease in prevalence is higher in Asians than in the rest of the
world.6 Between the years 2000 to 2025, there will be a 65.4%
increase in prevalence of hypertension in Asia compared with
a 51.2% increase in the rest of the world. This change is even
more severe in females, with a 81.6% increase in Asia
compared to a 54.4% increase in the rest of the world.6
In east Asian countries (China, Japan, and Korea), the death
rate attributable to stroke is higher than that due to CHD.15, 16
While hypertension is the most important risk factor for
stroke,17 the impact of hypertension on stroke and CHD in
Table 2
Classes of recommendations.
Classes of recommendation Definition Strength
Class I Evidence and/or general agreement that a given treatment of procedure
is beneficial, useful, effective
Is recommended/is indicated
Class II Conflicting evidence and/or a divergence of opinion about the usefulness/
efficacy of the given treatment or procedure
Class IIa Weight of evidence/opinion is in favor of usefulness/efficacy Should be considered
Class IIb Usefulness/efficacy is less well established by evidence/opinion May be considered
Class III Evidence or general agreement that the given treatment or procedure is
not useful/effective, and in some cases may be harmful
Is not recommended
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increase in systolic BP (SBP) of 15 mmHg, the hazard ratio for
CHD and stroke is higher for Asians than that for Cauca-
sians.18 In a clinical trial in patients with a history of stroke or
transient ischemic attack, treatment of hypertension resulted in
a 38% reduction in the risk of recurrent stroke in Asian pa-
tients, compared to a 20% reduction in Caucasians, with a
similar decrease in BP.20 This information suggested that
controlling hypertension is the most important strategy to
decrease cardiovascular events in Asian countries, especially
stroke.2.2. Hypertension in TaiwanIn a previous survey in Taiwan, the nationwide prevalence
rates of hypertension (defined by SBP 140mmHg or diastolic
BP [DBP]  90 mmHg) were 25% in men and 18% in women,
and that rate increased to 47% among individuals of age 60
years.8 The prevalence of hypertension in Taiwan is increasing
due to a surge in the prevalence rates of prehypertension, obesity
andmetabolic syndrome.21 Prehypertension is an important risk
factor for the development of hypertension in Taiwan, with an
odds ratio of 1.71, compared to normotensives.21 It is estimated
that 59% of patients with prehypertension would develop hy-
pertension after 8 years.21 Interestingly, in patients less than 60
years of age, the prevalence rate of hypertension is higher inmen
than inwomen.8After that threshold age,women aremore likely
to have hypertension than men. These findings were similar to
those from the US.22
In the report of the Nutrition and Health Survey in Taiwan
(NAHSIT) (1993e1996), the control rate of hypertension (by
JNC VI definition)23 in patients 19 years of age was only
2% in men and 5% in women.24 In the Taiwanese Survey on
Hypertension, Hyperglycemia, and HyperlipidemiaTable 3
Level of evidence.
Level of evidence A Data derived from multiple (2) randomized
clinical trials
Level of evidence B Data derived from a single randomized
clinical trial, meta-analyses, or large
non-randomized studies
Level of evidence C Subgroup analyses, post-hoc analyses,
retrospective studies, cohort studies, registries,
small studies, or expert opinion(TwSHHH) in 2002,8 the control rate in patients 19 years
of age was improved to 21.0% in men and 28.5% in women.
It is reasonable to believe that the implementation of the
National Health Insurance system since 1995 has contributed
to the improvement of hypertension control. More recently,
the control rate of hypertension has been further improved to
58.8% in a report from Southern Taiwan,25 by way of
implementation of the 2010 hypertension guidelines of
TSOC and frequent phone contacts by study nurses. How-
ever, the control rate of hypertension varies in different areas
in Taiwan; it reached as high as approximately 50% for
women in the northern area, but was less than 10% for men
in eastern parts of Taiwan, reflecting the disparity in medical
resources.9
The impact of controlling hypertension in Taiwan has been
demonstrated in the decrease in cardiovascular mortality. The
mortality rate attributed to stroke decreased from 64.8/100,000
in 1994 to 53.5/100,000 in 2002, and in heart disease, from
56.9/100,000 in 1994 to 50.9/100,000 in 2002.8 Stroke had
been the second leading cause of death in Taiwan for more
than 30 years until 2007, when CHD surpassed stroke to
become the second leading cause of death.
3. Definition and classification of hypertension
Both stroke and CHD mortality are positively correlated
with both office SBP (down to 115 mmHg) and office DBP
(down to 75 mmHg).26 It would be difficult to draw a line to
differentiate hypertensives from normotensives. But for
descriptive purposes and therapeutic guidance, cut-off BP
values are universally used. Hypertension is defined as values
140 mmHg in SBP, and/or 90 mmHg in DBP, using office
BP measurement, based on the evidence from randomized
controlled trials (RCTs) suggesting that treatment-induced
BP reductions are beneficial to patients with these BP
values (Table 5). We further stratified stages of hypertension
by a 20-mmHg increase in SBP and a 10-mmHg increase in
DBP, because doubling of CHD death has been observed by
the same increments in BPs in an epidemiological study26
(Table 5). For patients with diabetes, CHD, or proteinuric
chronic kidney disease (CKD) (special patient groups), a
SBP  130 mmHg and/or a DBP  80 mmHg were
considered high BPs (Sections 6.4, 6.5, 6.7). The staging of
hypertension was defined by the highest level of BPs, whether
systolic or diastolic.
Table 4
Comparison of the 2013 ESH/ESC hypertension guidelines, the 2014 JNC Report, and the 2015 TSOC/THS hypertension guidelines.
2013 ESH/ESC 2014 JNC Report 2015 TSOC/THS
Diagnosis flow chart   þ
Treatment flow chart  þ þ
Adjustment flow chart  þ þ
Life style modification þ  þ
Blood pressure targets þ
Universally <140/90
þ
<140/90 (<150/90 for age>60)
þ
<140/90 (or <130/80 for special patient groupsa)
Treatment in special conditions þ  þ
Treatment of associated risk factors þ  
Standards of IOM
Transparency ? ? þb
Conflict of interests Full disclosure Full disclosure Full disclosure
Group compositions
Advisory board member
N ¼ 55 N ¼ 51 N ¼ 53
Systemic review þc þd þe
Strength of recommendation þ þ þ
Articulation þ ? þ
External review þ þ þ
Updating þ þ þ
Appropriateness for Asians ? ? þ
ESC ¼ European Society of Cardiology; ESH ¼ European Society of Hypertension; IOM ¼ Institute of Medicine; JNC ¼ Joint National Committee; THS ¼
Taiwan Hypertension Society; TSOC ¼ Taiwan Society of Cardiology.
a Patients with diabetes, or coronary heart disease, or proteinuric chronic kidney disease.
b All presentations can be viewed on website (http://tw.i519.org/tsoc).
c Randomized controlled trials, meta-analyses, and cohort studies.
d Only randomized controlled trials.
e Randomized controlled trials, meta-analyses, non-randomized trials, subgroup analyses, post-hoc analyses, retrospective studies, cohort studies, registration
studies, small studies, especially focused on available data for Asians.
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surement, complemented by home BP monitoring (HBPM),
and ambulatory BP monitoring (ABPM).
4.1.1. Office blood pressure measurement
The measurement of BP is likely the single clinical pro-
cedure of greatest importance that is actually performed in the
sloppiest manner. The measurement of BP should follow the
noted recommendations.27 Table 6 summarized correct
methods for office BP measurement. Patient BP should be
measured in both arms during the initial visit, and then the armTable 5
Definition and classification of hypertension by office blood pressure
measurement.
Staging Systolic BP (mmHg) Diastolic BP (mmHg)
Normal <120 and <80
Prehypertension 120-139 or 80-89
Stage 1 hypertension 140-159 or 90-99
Stage 2 hypertension 160-179 or 100-109
Stage 3 hypertension 180 or 110
Isolated systolic hypertension 140 and <90
Systolic BP 130 mmHg or diastolic BP80 mmHg are considered high
blood pressures in special patient groups (coronary heart disease, diabetes, and
proteinuric chronic kidney disease), and also in patients who receive antith-
rombotics for stroke prevention. (Modified from Chiang et al.9 with
permission.)with a higher BP should be used in the following visits. When
orthostatic hypotension is suspected, especially in elderly
patients or diabetic patients, BP should be measured at 1
minute and 3 minute intervals after assumption of standing
position. Orthostatic hypotension is a strong predictor of CV
events and total mortality.28, 29
The “gold standard” device for office BP measurement has
been the mercury sphygmomanometer, but these are being
removed from clinical practice because of environmental
concerns about mercury contamination.27 Therefore, auscul-
tatory or oscillometric semiautomatic sphygmomanometers
are typically used in most practices. Validated devices are
recommended, and several lists of validated devices are
available online (http://www.bhsoc.org; or http://www.
hypertension.ca).
Although the data from the Framingham Heart Study
showed that DBP is a stronger predictor for CHD than SBP in
patients less than 50 years of age,27 it is generally believed that
SBP is a more important predictor for overall cardiovascular
risk in elderly patients (65 years or older).30-32 Because about
75% of people with high BP are over the age of 50, the burden
of disease is mainly due to elevation of SBP.33 It has also been
shown that anti-hypertensive drugs improved patient outcomes
mainly through lowing SBP.34, 35 However, SBP is more
difficult to control compared with DBP.35
4.1.2. Ambulatory blood pressure monitoring (ABPM)
ABPM has become a useful tool in the diagnosis and
management of hypertension.36 ABPM is superior to office BP
Table 6
Correct methods for office blood pressure measurement.
Before measurement
Timing
1 hour Avoiding coffee, food, smoking, decongestants
30 minutes Avoiding exercise
5 minutes Sitting calmly
Preparation Emptying bladder and bowel, and removing
all clothing that covers the location of cuff
placement
Environment Calm and warm place
During measurement
Body position Seated, back supported, legs uncrossed, feet
flat on floor, and relaxed
Arm Supported, using the arm with higher value
Cuff at heart level, using appropriate sized one
Measurement Taking two measurement, spaced 1-2 minutes
apart, and additional measurement if needed
Measuring heart rate by pulse palpation
(at least 30 seconds) after the second
measurement
For patients with atrial fibrillation, measuring
blood pressure manually, using direct
auscultation over the brachial artery
When suspecting orthostatic hypotension,
measuring blood pressure 1 and 3 minutes
after assumption of standing position
After measurement
Blood pressure readings Averaging, but not rounding them
Recording
Table 7
Definition of hypertension by HBPM and ABPM.
Category Systolic blood
pressure (mmHg)
Diastolic blood
pressure (mmHg)
HBPM 135 or 85
ABPM 130 or 80
Daytime 135 or 85
Nighttime 120 or 70
ABPM ¼ ambulatory blood pressure monitoring; HBPM ¼ home blood
pressure monitoring. (Modified from Chiang et al.9 with permission.)
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events.37, 38 In 2001, the Centers for Medicare and Medicaid
Services in the United States approved ABPM for reim-
bursement for the identification of individuals with white-coat
hypertension; in 2011 the National Institute for Health and
Care Excellence (NICE) in the United Kingdom recommended
that ABPM be offered as a cost-effective technique for all
people suspected of having hypertension.36 Unfortunately, the
National Health Insurance Administration in Taiwan has not
included ABPM in its reimbursement lists.
The ABPM devices are typically programmed to take
readings every 15 to 30 minutes throughout the day and night.
At the end of the recording period, the readings are down-
loaded into a computer. Standard protocols are used to eval-
uate the accuracy of the devices. Approved devices are usually
accurate to within 5 mm Hg of readings taken with a mercury
sphygmomanometer.39 Methodological details can be referred
to the practice guidelines of ESH,36 and would not be
mentioned here. Cut-off values for the definition of hyper-
tension for ABPM were shown in Table 7. Additionally, ad-
vantages and weaknesses of ABPM were shown below:
4.1.2.1. Advantages of ABPM36
 Is a much stronger predictor of cardiovascular events than
office BP
 Provides larger number of BP readings
 Identifies white-coat hypertension, and masked
hypertension
 Discloses nocturnal hypertension, and dipping patterns Provides averaged daytime, night-time, and 24-hour
values
 Assesses BP variability over 24 hours
 Evaluates the 24-hour efficacy of antihypertensive drugs
4.1.2.2. Weaknesses of ABPM36
 Cost (reimbursement issue)
 Limited availability in private practice
 Discomfort in patients
 Repeated measurement not likely in short term.
The averaged night-time BP has become a stronger pre-
dictor than averaged daytime BP.40-42 The sleep-time BP mean
has also been reported to be the most significant prognostic
predictor of cardiovascular morbidity and mortality.43 A pa-
tient's BP normally decreases during the night, defined as a
“dipping” pattern.44 It is generally agreed that a night-time BP
fall of >10% of daytime values (night-day ratio <0.9) is the
cut-off value for normal dipping.39 Approximately 70% of
individuals dip 10% at night, while 30% have non-dipping
patterns.44 A different degree of dipping has been proposed,
but the reproducibility of dipping pattern is limited.10
Early morning hypertension defined as elevation of
averaged BP over the 2 hours after awaking has been re-
ported to be associated with higher risk of stroke.45 Both
HBPM and ABPM were interchangeable methods for the
assessment of early morning hypertension.46 Circumstantial
evidence for the validity of early morning hypertension as
an index of disease risk is provided by a peak in myocardial
infarction and stroke compared with other periods of the
day.47 A morning BP surge, on the other hand, is an in-
crease in BP occurring from the night-time to the early
morning.47 Morning BP surge can be measured reliably by
ABPM. Similar to early morning hypertension, it has been
reported to be a risk factor for cardiovascular events,48
especially hemorrhagic stroke.49 In a recent analysis of
5,645 individuals recruited from eight different countries,
the morning BP surge was associated with a 30e45% in-
crease in the risk of cardiovascular events.50
4.1.3. Home blood pressure monitoring (HBPM)
High BP detected by HBPM is more closely related to
hypertension-related TOD and predicts the risk of cardiovas-
cular events better than office BP measurement.51, 52 Some
studies and meta-analyses have suggested that HBPM is as
good as ABPM and superior to office measurements in regard
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BP should be measured by validated semi-automated oscillo-
metric (electric) devices, and under similar requirements as
office BP measurement (Table 6).
A minimum of 12 measurements and up to 25 measure-
ments over a few days might be desirable.56 Two morning
readings and 2 evening readings for 7 days immediately before
each visit, excluding the readings from the first day, would be
measured and stored in devices for HBPM.57 Thus, there
would be 12 readings either in the morning or in the evening,
with a total of 24 readings. These readings can be averaged for
each visit. Physicians may use separated averages of morning
or evening BP to adjust the timing of administration of anti-
hypertensive drugs. Cut-off values for the definition of hy-
pertension for HBPM were shown in Table 7. Advantages and
weakness of HBPM were shown below:
4.1.3.1. Advantages of HBPM36, 57
 Is a stronger predictor of cardiovascular events than office
BP
 Provides a larger number of BP readings
 Can be repeated more frequently than ABPM
 Identifies white-coat hypertension, and masked
hypertension
 Evaluates the efficacy of antihypertensive drugs at
different times of the day and night, except sleep
 High acceptance by patients
 Relatively low cost
4.1.3.2. Weaknesses of HBPM36, 57
 Necessity for patient training (simple for automated
devices)
 Possible use of un-validated devices
 Lack of night time recordings.
The investigators of the TASMIN-SR (The Targets and
Self-Management for the Control of Blood Pressure in Stroke
and at Risk Groups) recently studied the impact of BP self-
monitoring at home with self-titration of antihypertensive
medication, compared with usual care, on SBP among high-
risk patients with existing cardiovascular disease, diabetes
mellitus, or CKD.58 The mean baseline BP was 143.1/
80.5 mmHg and 143.6/79.5 mmHg in the intervention and the
control groups, respectively. The mean BP decreased to 128.2/
73.8 mmHg and 137.8/76.3 mmHg in the intervention and the
control groups, respectively, after 12 months.58 There was a
difference of 9.2 mmHg (p < 0.05) in SBP and 3.4 mmHg in
DBP between groups. The authors concluded that self-
management of BP in patients with or at high risk of cardio-
vascular disease resulted in lower SBP at 12 months.584.2. White-coat hypertensionWhite-coat hypertension is defined in subjects who have
elevated office BP (140/90 mmHg), but with ABPM < 130/
80 mmHg,36 or HBPM < 135/85 mmHg.57 The term should bereserved for un-treated patients. In patients who have received
treatment, the term “white-coat effect” is preferred.44 The
prevalence of white-coat hypertension was estimated to be
around 10e15%.59, 60 However, in patients with elevated of-
fice BP, white-coat hypertension was common, particularly in
the untreated group (42.9%).60 The long-term prognosis of
untreated patients with white-coat hypertension is controver-
sial. In a meta-analysis using IDACO (International Database
on Ambulatory Blood Pressure Monitoring in relation to
Cardiovascular Outcomes) Population data, the adjusted haz-
ard ratio of subjects with white-coat hypertension was similar
to subjects with normal BP (1.17, p ¼ 0.29).61 On the contrary,
data from IDHOCO population (International Database of
Home Blood Pressure in Relation to Cardiovascular Outcome)
show that among untreated subjects cardiovascular risk was
higher in those with white-coat hypertension compared with
normotensive subjects (adjusted hazard ratio of 1.42,
p ¼ 0.02).60 In a recent study from Taiwan using ABPM to
define white-coat hypertension, 15-year cardiovascular mor-
tality was higher in subjects with white-coat hypertension.62 It
is suggested that ABPM and HBPM are complementary for
the diagnosis of white-coat hypertension.60 This view was
supported by a recent analysis of the PAMELA general pop-
ulation study.63 Among subjects with white-coat hypertension,
those with low home and ambulatory BP had lower cardio-
vascular mortality than those with only one of them being
low.63
It is debatable that subjects with white-coat hypertension
need treatment. The majority of evidence supports increased
TOD in cross-sectional studies of subjects with white-coat
hypertension, including left ventricular hypertrophy and
increased carotid intima-media thickness.64, 65 Furthermore, a
higher prevalence of metabolic derangement has been re-
ported,62, 66 including increased new-onset diabetes.67 In a
Taiwanese study, subjects with white-coat hypertension were
characterized by higher arterial stiffness and lower estimated
glomerular filtration rate.62 We suggest that patients with
white-coat hypertension should be treated with life style
modification (LSM), and regularly followed up by ABPM or
HBPM to detect any evidence of progression to sustained
hypertension.
For treated patients who have “white-coat effect”, the car-
diovascular events were lower than in those with resistant
hypertension, but similar to patients with well-controlled hy-
pertension.68, 69 Notably, 20 to 25% of patients with white-
coat effect would develop true resistant hypertension within
3 to 6-months of follow-up.70 Therefore, continued HBPM or
ABPM are advised.4.3. Masked hypertensionMasked hypertension is defined in untreated subjects who
have normal office BP (<140/90 mmHg), but with elevated
ABPM (130/80 mmHg),36 or elevated HBPM (135/
85 mmHg).57 Masked uncontrolled hypertension is defined in
treated patients utilizing similar criteria.36, 57 The prevalence
of masked hypertension was estimated to be around 10-
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patients with normal BP.71 In the Masked Hypertension Study
in the untreated subjects, it was shown that the prevalence of
masked hypertension increased to 34% in subjects with pre-
hypertension, and reached 52% in subjects with higher pre-
hypertensive BP (SBP 130139 mmHg or DBP
8089 mmHg), whereas the prevalence of masked hyperten-
sion was only 3.9% in participants with normal office BP (SBP
<120 mmHg and DBP < 80 mmHg).71 Other studies have
similarly shown that office BP in the upper prehypertensive
range predicts masked hypertension.72 Masked hypertension
was not uncommon in patients with diabetes,73 CKD,74 and
obstructive sleep apnea syndrome.75 On the other hand, the
prevalence of masked uncontrolled hypertension was high (up
to 41.4%),60 and highlights the need for ABPM or HBPM in
all treated patients.60 Meta-analyses of prospective studies
demonstrated that subjects with masked hypertension had two-
fold higher cardiovascular event rates than normotensives,
similar to the event rates in patients with sustained hyperten-
sion.59, 76, 77
Anti-hypertensive management may be considered in pa-
tients with masked hypertension, but there are currently no
RCTs that have evaluated this strategy, and the best method to
identify subjects with masked hypertension has not yet been
established.44 A diagnostic algorithm using ABPM (or HBPM)
for follow-up has been proposed to evaluate subjects with
masked hypertension, if their office BP is in the pre-
hypertensive range.78 If office BP is <120/80 mmHg, there
will be no need to arrange ABPM, as the prevalence of masked
hypertension is quite low in this group.Fig. 1. Diagnosis algorithm. This algorithm does not apply to very elderly patients (a
For special patient groups (coronary heart disease, diabetes, or proteinuric chron
70e79 mmHg; x <120/70 mmHg). ABPM ¼ ambulatory blood pressure monitor
monitoring; LSM ¼ life style modification; m ¼ month; TOD ¼ target organ d
albuminuria, or asymptomatic atherosclerosis [carotid intima-media thickening or a
year. (Modified from Chiang et al.9 with permission.)4.4. Diagnosis algorithmA diagnosis algorithm was proposed in Fig. 1. For patients
presenting with office BP  140/90 mmHg (or 130/
80 mmHg in special patient groups, i.e. diabetes, CHD, and
proteinuric CKD), physical examination (Section 5.2) and
routine laboratory tests (Section 5.3) (Table 8) should be
performed, and a medical history obtained (Section 5.1).
After 2 weeks to 1 month, office BP can be rechecked. If
office BP is still <140/90 mmHg (or <130/80 mmHg in
special patient groups), continued outpatient clinic follow-up
is suggested (unless in patients who have office BP in the
prehypertension range [120-139/80-89 mmHg, or 120-129/
70-79 mmHg in special patient groups] in whom ABPM or
HBPM can be performed in 3-6 months to confirm the
diagnosis of masked hypertension). For patients who have
repeated office BP 140/90 mmHg (or 130/80 mmHg in
special patient groups), physicians should look for evidence
of TOD (including left ventricular hypertrophy by electro-
cardiogram, microalbuminuria, or asymptomatic atheroscle-
rosis [carotid intima-media thickening or aortic plaque],
ankle-brachial index<0.9, or increased pulse wave velocity).
In case of positive TOD, physicians should proceed to the
Treatment Algorithm (Fig. 2). If there is no evidence of TOD,
HBPM or ABPM should be performed to rule out the pos-
sibility of white-coat hypertension. If HBPM is 135/
85 mmHg or ABPM 130/80 mmHg, physicians should
proceed to the Treatment Algorithm (Fig. 2). For patients
with normal HBPM and normal ABPM, continued follow-up
is suggested. Physicians can arrange ABPM or ask patients toge 80 years) because their treatment threshold and targets are 150/90 mmHg.
ic kidney disease), lower BPs are applied (* 130/80 mmHg; # 120e129/
ing; BP ¼ blood pressure; FU ¼ follow-up; HBPM ¼ home blood pressure
amage (including left ventricular hypertrophy by electrocardiogram, micro-
ortic plaque], ankle-brachial index<0.9, or increased pulse wave velocity); y ¼
Fig. 2. Treatment algorithm. This algorithm is not applicable in very elderly patie
disease; DM ¼ diabetes mellitus; SPC ¼ single-pill combination. (Modified from
Table 8
Laboratory tests.
Routine tests
Hemoglobin and hematocrit
Serum creatinine with estimated creatinine clearance (Cockroft-Gault
formula) or glomerular filtration rate (Modification of Diet in Renal Disease
formula)
Serum sodium, potassium and calcium
Fasting glucose
Total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides
Serum uric acid
Urinalysis
Electrocardiogram
Chest X-ray
Recommended tests
Oral glucose tolerance test or HbA1C (if fasting plasma glucose 100 mg/
dL)
High sensitivity C reactive protein
Quantitative microalbuminuria/proteinuria
Fundoscopy
Echocardiography
Carotid ultrasound
Home and ambulatory blood pressure monitoring
Ankle-brachial index
Pulse wave velocity
Extended evaluation (domain of the specialist)
Further search for cerebral, cardiac, renal and vascular damage. Mandatory
in complicated hypertension
Search for secondary hypertension when suggested by history, physical
examination or routine tests: measurement of renin, aldosterone,
corticosteroids, catecholamines in plasma and/or urine; angiographies; renal
and adrenal ultrasound; computer-assisted tomography; magnetic resonance
imaging
(Modified from Chiang et al.9 with permission.)
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after the first visit), and manage patients accordingly.
Although the cut-off values of 135/85 mmHg for HBPM and
130/80 mmHg for ABPM are well established, the cut-off
values of HPBM and ABPM for special patient groups
(diabetes, CHD, proteinuric CKD) are unknown. We may
consider that the cut-off values for HBPM and ABPM should
be lower than office BP thresholds (130/80 mmHg) in special
patient groups.
5. Evaluation5.1. Medical historyA complete medical history should be taken during the first
visit for patients with high BP. The information of interest to
clinicians is related to treatment threshold, BP targets, and
choice of management strategy. Medical history includes:
 Previous cardiovascular events and diseases: CHD, stroke
or transient ischemic attack, diabetes, heart failure, CKD,
peripheral artery disease, and sleep apnea.
 Personal history: dietary habit, salt intake, alcohol intake,
smoking history, and exercise habit.
 Previous drug history: anti-hypertensive drugs, non-steroid
anti-inflammatory drugs (NSAIDs), cyclooxigenase-2
(COX-2) inhibitors, steroids, oral contraceptives,
migraine medications, cold remedies (containing pseu-
doephedrine), systemic or intra-vitreal use of anti-vascular
endothelial growth factor (anti-VEGF), etc.nts (age 80 years). CHD ¼ coronary heart disease; CKD ¼ chronic kidney
Chiang et al.9 with permission.)
11C.-E. Chiang et al. / Journal of the Chinese Medical Association 78 (2015) 1e475.2. Physical examinationPhysical examination plays an essential role in the assess-
ment of hypertensive patients. The purposes of physical ex-
aminations include establishing the diagnosis and determining
the severity of hypertension, searching for signs of secondary
hypertension and TOD, and refining global cardiovascular
risk.9 Initially, BP should be measured correctly (Section
4.1.1) (Table 6). Physical examination should include the
followings: 1) calculation of body mass index (BMI); 2) in-
spection of Cushingoid appearance including moon face,
buffalo hump, truncal obesity, and wide purple striae; 3)
evaluation of optic fundi for hypertensive retinopathy; 4)
palpation of the thyroid gland for hyperthyroidism; 5)
auscultation of carotid, abdominal and femoral bruits for
renovascular disease and peripheral artery disease; 6) auscul-
tation over the back for a loud murmur suggesting coarctation
of aorta; 7) comprehensive examination of the heart and lungs
for left ventricular hypertrophy, and ventricular gallop of
congestive heart failure; 8) examination of the abdomen for
enlarged kidneys, masses, and pulsation of abnormal aorta; 9)
palpation of the lower extremities for edema and pulses; and
10) a complete neurological assessment.9 The aforementioned
evaluation should be undertaken in every patient in the first
visit.5.3. Laboratory testsLaboratory tests aim to search for additional risk factors,
provide evidence of secondary hypertension, and look for
TOD (Table 8). A more detailed diagnostic work-up should be
performed in younger patients, patients with very high BP, and
patients with TOD. Routine tests should be considered in
every patient at the first visit. Recommended studies are
optional (Table 8). Measurement of urinary albumin excretion
or albumin/creatinine ratio is strongly recommended in
Taiwan, a country with the highest prevalence of ESRD in the
world.79 High-sensitivity C reactive protein (hs-CRP) predicts
the incidence of cardiovascular events and optimizes the use of
statins in hypertensive patients who have a high cardiovascular
risk.805.4. Central blood pressureAll the traditional ways of measuring BP, including office
BP measurement, HBPM, and ABPM, use recordings from the
brachial arteries, and may be different from the central BP
measured in the ascending aorta or carotid arteries, due to the
well-recognized BP amplification from the central aorta to the
peripheral arteries.81 Recent data suggested that central BP
may be more relevant than peripheral BP in predicting TOD
and cardiovascular outcomes.82 although central and periph-
eral BP may respond differently to antihypertensive medica-
tion in RCTs,83 end-organ changes after antihypertensive
medication are more strongly related to changes in central BP
than peripheral BP.84 The individual discrepancies between
central BP and peripheral BP may be substantial and highlyvariable, and may be magnified during hemodynamic changes
or after pharmacological interventions.83 Thus, BP measure-
ments in the peripheral arteries cannot serve as a direct sub-
stitute for their central counterpart.85 More importantly, an
office measurement of central BP is not inferior to ambulatory
BP in the prediction of future outcomes.86
Currently, central BP can be obtained non-invasively with
either tonometry-based87 or cuff-based techniques.88 Using an
outcome-driven approach to examine the discriminatory abil-
ity of central BP for long-term cardiovascular outcomes,89 an
operational threshold for central BP has been derived and
validated in two independent Taiwanese cohorts.90, 91 A cen-
tral BP cut-off value of 130/90 mm Hg has a greater
discriminatory power for long-term events, and can be
considered to be implemented for the management of hyper-
tension in routine daily practice.92 Central BP may have
higher sensitivity and negative predictive value than peripheral
BP in the diagnosis of hypertension.93
Recommendation
 Measurement of central BP with a cut-off value of 130/
90 mmHg is recommended when a diagnosis of hyper-
tension is clinically suspected but cannot be established by
current conventional BP criteria. (COR IIb, LOE B)5.5. Blood pressure variabilityBP is not static but has significant fluctuations. The phe-
nomenon of BP variability (BPV) is well-recognized as short-
term fluctuation occurring within a 24-hour period, including
beat-to beat, minute-to-minute, hour-to-hour, and day-to-night
variations. Long-term variations including day-to-day as well
as more prolong interval such as week-to-week, month-to-
month, and even seasonal changes are noted.94 BPV is thought
to be the result of complex interactions between intrinsic
cardiovascular physiologic regulation and extrinsic environ-
mental and behavior factors, but are not yet completely
elucidated. Although previous studies have shown increased
BPV was associated with adverse cardiovascular conse-
quences, the clinical utility of BPV is not yet well
established.10
Most of the evidence suggesting an association between
BPV and cardiovascular events are based on observational
studies and post-hoc analyses of clinical trials.95 Prospective
studies have provided evidence that increased short-term BPV
with 24 hours independently predicted progression of sub-
clinical organ damage, structural cardiac and vascular
changes, cardiovascular events, and cardiovascular mortal-
ity.96-98 ABPM is used for assessment of BPV within 24 hours.
It is possible to perform the calculation of standard deviation
(SD) of average systolic, diastolic, and mean arterial pressure
values over the 24-hour period, or during the daytime and
night-time sub-periods.99 The SD can be weighted by the 24-
hour mean value, and has been proposed as a method to
exclude day-to-night BP changes from the quantification of
overall 24-hour SD.94 Since BPV is largely dependent on
Table 9
Causes of secondary hypertension.
Acute stress-related secondary
hypertension
Isolated systolic hypertension due
to an increased cardiac output
Diseases of the aorta Neurological causes
Coarctation of the aorta GuillaineBarre syndrome
Rigidity of the aorta Idiopathic, primary, or familial
dysautonomia
Drugs and exogenous hormones Increase intracranial pressure
Endocrine Quadriplegia
Acromegaly Obstructive sleep apnea (OSA)
Adrenal cortical Pregnancy induced hypertension
Apparent mineralocorticoid
excess
Renal
Cushing syndrome Increased intravascular volume
Primary aldosteronism Primary sodium retention
(Liddle's syndrome)
Adrenal medulla Renal parenchymal disease
Carcinoid syndrome Renin-producing tumors
Pheochromocytoma Renal vascular disease
Hyperparathyroidism
Hyperthyroidism
Hypothyroidism
(Modified from Chiang et al.9 with permission.)
12 C.-E. Chiang et al. / Journal of the Chinese Medical Association 78 (2015) 1e47mean BP, the average SD of BP can also be divided by the
corresponding mean BP and multiplied by 100 to express a
normalized measure of BPV as a coefficient of variation.94
ABPM also provides information on diurnal BP changes.
The prognostic relevance of nocturnal BP and reduced night-
time BP dipping has been assessed in several studies. A
community study in Taiwan has shown that night-time BP
drop was associated with TOD.100
Evidence also suggests that increased mid-term (such as
day-to-day) BPV is associated with increased cardiovascular
events. The Ohasama study provided the evidence that
increased day-to-day variability in SBP assessed by HBPM is
associated with an increased risk of cardiovascular mortal-
ity.101 HBPM is an appropriate method for the assessment of
mid-term and long-term BPV.94 HBPM allows day-to-day BP
measurement in fairly standardized conditions, and the use of
HBPM is recommended in current international guidelines.10
Increased long-term BPV such as visit-to-visit variability is
associated with TOD and cerebral damage in previous
studies.102, 103 Longitudinal studies and post-hoc analyses of
clinical trials in hypertension have shown that increased intra-
individual visit-to-visit variability is predictive of fatal and
non-fatal cardiovascular and cerebrovascular events, and all-
cause mortality.104-106
Currently, no large randomized placebo-controlled trials are
available to study the effect of antihypertensive drugs. A post-
hoc analysis of data from ASCOT and MRC-elderly showed
that long-term intra-individual visit-to-visit variability might
be affected differently by various classes of antihypertensive
drugs, and that these differences might reflect various effects
of different drugs on BP.104 The most important finding of the
analysis was calcium-channel blocker-based regimen was
associated with lower intra-individual BPV and a lower inci-
dence of stroke than a beta-blocker-based regimen. However,
before BPV is recommended as a routine measure or as a
target for antihypertensive treatment, further prospective
outcome studies should be conducted.5.6. Screening for secondary hypertensionThe causes of secondary hypertension are listed in Table 9.
A secondary form of hypertension should be suspected in
patients with younger or older onset of hypertension, marked
BP elevation, sudden onset or worsening of hypertension, poor
BP response to drug therapy, and significant TOD at initial
presentation. Screening for secondary hypertension includes
history taking, physical examination, and laboratory tests.
Renal parenchymal disease is the leading cause of sec-
ondary hypertension. Bilateral upper abdominal masses upon
physical examination could be detected in patients with
polycystic kidney disease. Renal ultrasound provides the
necessary anatomical data including kidney size and shape,
cortical thickness, urinary tract obstruction and renal masses.
Serum creatinine concentration and urinalysis are screening
tests for renal parenchymal disease.
Renovascular hypertension is the second most common
cause of secondary hypertension. Renal artery stenosis due toatherosclerosis or fibromuscular dysplasia is the leading cause
in the elderly and younger population, respectively. It should
be considered in those with renal artery bruit, unexplained
hypokalemia, hypertension onset before age 30 years or
worsening after age 55 years, resistance to antihypertensive
therapy, sustained rise in creatinine after initiation of angio-
tensin converting enzyme (ACE) inhibitor or angiotensin re-
ceptor blocker (ARB), presence of hypertensive retinopathy, or
flash pulmonary edema.107 Renal ultrasound can be used as a
screening tool to determine the longitudinal diameter of both
kidneys, and a difference of >1.5 cm in length between two
kidneys suggested a diagnosis of renal artery stenosis.108
Color Doppler ultrasonography is helpful for detection of
renal artery stenosis. Three-dimensional, gadolinium-
enhanced magnetic resonance renal angiography or spiral
computed tomography renal angiography is the diagnostic
choice for renovascular hypertension. Digital subtraction
angiography is the gold standard for detection.
Pheochromocytoma should be considered in patients with
paroxysmal BP elevation. The typical symptoms of this dis-
ease include headache, perspiration, palpitations, and pallor.
The diagnosis is confirmed by an increase in plasma or urinary
catecholamines or their metabolites.
Serum potassium level is a routine screening test. It has
been suggested that patients with unprovoked hypokalemia or
truly resistant hypertension should be evaluated for primary
aldosteronism.109 The disease can be confirmed by the flu-
drocortisone suppression test of aldosterone and renin, under
standardized conditions.110 A cut-off of aldosterone to renin
ratio >100 ng/dL per ng/mL/hr and plasma aldosterone
>20 ng/dL after captopril differentiates bilateral aldosterone-
producing adenoma from bilateral adrenal hyperplasia.111
About 80% of patients with Cushing's syndrome have hy-
pertension. The syndrome is usually suggested by the typical
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obesity. The determination of 24-hour urinary cortisol excre-
tion is the most practical and reliable diagnostic test and a
value >110 mmol (40 mg) is highly suggestive of Cushing's
syndrome.
It is important to consider sleep apnea in obese hyperten-
sive patients. Signs and symptoms include daytime somno-
lence, impaired concentration, unrefreshing and restless sleep,
choking episodes during sleep, witnessed apneas, nocturia,
irritability and personality changes, decreased libido, and
increased motor vehicle accidents. Furthermore, hypertensive
patients with “non-dippers” on ABPM should be investigated
for obstructive sleep apnea. The gold standard diagnostic tool
for assessing obstructive sleep apnea is polysomnography.
Coarctation of the aorta is a rare form of hypertension in
children and young adults. A mid-systolic murmur can be
heard over the anterior part of the chest and back. The femoral
pulse is weak or delayed relative to the radial pulse. Hyper-
tension is found in the upper extremities concomitantly with
low or unmeasurable BP in the legs.
Finally, medication history should be reviewed carefully.
Substances or drugs that can raise BP include pills used to
treat common colds such as licorice in antitussive syrup, oral
contraceptives, steroids, NASIDs, cocaine, amphetamines,
erythropoietin, cyclosporin, tacrolimus, and anti-VEGF.
6. Blood pressure thresholds and targets
In the most robust meta-analysis of individual data from 1
million adults in 61 prospective studies (11 million person-
years), both stroke and CHD mortality increased continu-
ously from a nadir of 115 mmHg in SBP and a nadir of
75 mmHg in DBP.26 Similarly, in the Asia Pacific Cohort
Study Collaboration study consisting of data from 425,325
participants (3 million patient-years), the risk of stroke and
CHD started to increase from 115 mmHg in SBP and from
75 mmHg in DBP.112 More recently, in a study of a cohort of
1.25 million patients from United Kingdom, the lowest risk for
cardiovascular disease was in people with SBP of 90-
114 mmHg and DBP of 60-74 mmHg.32 In contrast, in a recent
publication from the Atherosclerosis Risk in Communities
Study (ARIC) it was found that there was no difference in
incident cardiovascular event-free survival among those in the
standard SBP group (120-139 mmHg) vs the low SBP group
(<120 mmHg).113 It would be difficult to define thresholds for
starting treatment, and it would be even more difficult to set
targets for BP control.
Recently, 2013 ESH/ESC hypertension guidelines defined a
universal target of <140/90 mmHg for all patients, except the
very elderly (target of <150/90 mmHg for age 80 years).10
The 2014 JNC report took similar steps, and further raised
the target to <150/90 mmHg for patients aged 60 years,11
though 5 members of the committee of 2014 JNC report
published a minority view refusing to compromise with a
target of 150/90 mmHg for aged 60 years.114 It has been
estimated that the proportion of older patients (60 years)
with treatment-eligible hypertension would decrease from68.9% under JNC7115 to 61.2% under the 2014 JNC report.116
This translates to a decrease in treatment-eligible patients of
5.8 million in the US in whom treatment is no longer
needed.116 The proportions of patients reaching BP goals
would, however, artificially increase from 40.0% under
JNC7115 to 65.8% under the 2014 JNC report.116
Because only a few RCTs were available to compare
different BP targets, disparity in BP targets among different
hypertension guidelines is not uncommon. Two ongoing trials
are much anticipated. The Systolic Blood Pressure Interven-
tion Trial (SPRINT) is an RCT that compares two targets
(<140 mmHg and <120 mmHg) in patients aged 50 years
with evidence of cardiovascular disease, CKD, 10-year Fra-
mingham cardiovascular disease risk score 15%, or age 75
years.117 The SPRINT trial has completed the enrollment
(n ¼ 9361) and the results will be available in the Fall of 2017.
The Optimal Blood Pressure and Cholesterol Targets for
Preventing Recurrent Stroke in Hypertension (ESH-CHL-
SHOT) is an RCT (NCT01563731) that compares three SBP
targets (<145 mmHg, <135 mmHg, and <125 mmHg) in
patients aged 65 years with prior stroke or transient ischemic
attack. The ESH-CHL-SHOT trial will enroll 7500 patients
and has been started in the Fall of 2012.6.1. J-curve revisitThe J-curve (or U-curve) phenomenon was first mentioned
in 1979.118 A study conducted in 169 patients with severe
hypertension disclosed a relative 5-fold risk of myocardial
infarction in those who had achieved a DBP <90 mmHg
compared with a DBP in the range of 100e109 mmHg.118
Coronary blood flow, which occurs predominantly in the
diastole, may cease at a myocardial perfusion pressure
<40 mmHg.119 More recently, there have been some data on
the J-curve phenomenon for SBP.120 It is generally believed
that the “J-curve” phenomenon is true, and there must be a
lowest value of BP (nadir), which represents a point at which
BP is too low to maintain perfusion of vital organs, particu-
larly the heart. The precise question remains-where is the
nadir?
In general, data from large-scaled epidemiological studies
did not support the concept of the J-curve phenomenon. In 1
million subjects with or without risk factors, but free from
cardiovascular diseases, both CHD and stroke mortality
appeared to begin at around 115/75 mmHg, without any J-
curve phenomenon.26 In a cohort of 1.25 million subjects,
initially free from cardiovascular disease, the lowest risk for
cardiovascular disease was in people with SBP of 90-
114 mmHg and DBP of 60-74 mmHg, without any evidence of
J-curve phenomenon.32 In the Multiple Risk Factor Interven-
tion Trial (MRFIT) which enrolled 332,554 subjects without
end organ damage, the lowest risk of ESRD was found in
subjects with a BP of <120/80 mmHg, without any J-curve
phenomenon.121 In the UK prospective diabetes study
(UKPDS) 36, the lowest risk of all-diabetes related macro- and
micro-vascular endpoints were in those patents with SBP less
than 120 mm Hg, without any J-curve phenomenon.122 In the
Table 10
Blood pressure targets.
Categories Targets (mmHg) COR LOE
Primary prevention <140/90 IIa B
Secondary prevention
Diabetes <130/80 I B
CHD <130/80 I B
Stroke <140/90 I A
CKD <140/90 I A
CKD with proteinuria <130/80 IIb C
Very elderly (age 80 years) <150/90 IIa B
Patients receiving
antithrombotics for stroke
prevention
<130/80 I B
CHD ¼ coronary heart disease; CKD ¼ chronic kidney disease; COR ¼ class
of recommendation; LOE ¼ level of evidence.
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lowest risk of CHD and stroke was found in patients with a BP
<120/80 mmHg, without a J-curve phenomenon.112
Among RCTs, it is also uncommon to find any J-curve
phenomenon if cardiovascular endpoints were evaluated pro-
spectively, though the BP levels obtained in RCTs were
generally higher than what we have mentioned in the epide-
miological studies. In the three most important RCTs in iso-
lated systolic hypertension (SHEP, Syst-Eur, Syst-China),
stroke risk was significantly decreased in the treatment group
compared to the placebo group.123-125 No J-curve phenomenon
was observed. In fact, the DBP in the treatment group in the
SHEP trial was only 68 mmHg, and the risk of myocardial
infarction was still significantly decreased by 33%.123
Most of the data suggesting a J-curve phenomenon came
from post-hoc analyses of RCTs.120, 126-129 One should be
aware that these RCTs were not designed to compare the ef-
fects of different BP targets, and they were mostly comparing
different drugs. As pointed out by a recent review,130 the main
limitations of post-hoc analyses are 1) lack of randomization,
and 2) very small number of patients in the group of patient
with low or very low achieved BP.
1). Lack of randomization: There are very few RCTs
comparing different BP targets. Most of the RCTs were
compared the effects of different drug or different drug
combinations. In post-hoc analyses, investigators tried to
study the outcomes based on different ranges of achieved
BP in trials. Therefore, patients were not randomized into
different BP categories, and the baseline risk factors or co-
morbidities were not evenly distributed in different BP
groups. Both measurable and un-measured confounding
factors were imbalanced, a major weakness in these kind
of analyses. For instance, in a key post-hoc analysis of the
INVEST trial, the achieved systolic and diastolic BPs were
categorized into 7 groups respectively (SBP:  110, >110-
120, >120-130, >130-140, >140-150, >150-
160, >160 mmHg; DBP:  60, >60-70, >70-80,
>80-90, >90-100, >100-110, >110 mmHg).126 Pa-
tients with an achieved SBP 110 mmHg, when compared
to patients with an achieved SBP of >130-140, had
higher baseline cardiovascular diseases or co-morbidities
including: myocardial infarction (47.9% vs 30.1%), cor-
onary artery bypass graft (32.9% vs 27.9%), stroke or
transient ischemic attack (8.5% vs 7.1%), left ventricular
hypertrophy (28.6% vs 19.8%), heart failure (15.0% vs
4.4%), and cancer (6.8% vs 3.2%). Similar trends were
observed when comparing patients with a DBP of
60 mmHg vs >80-90 mmHg. These observations have
repetitively been shown in other post-hoc analyses.120, 127-
129 In fact, when all these confounders were fully adjusted
in the post-hoc analyses of the INVEST trial, the J-curve
phenomenon disappeared.126 The worse outcome in pa-
tients with lower BP is attributable not to a lower BP, but
to the effect of concomitant diseases (“reverse causality”).
The “reverse causality” has also been observed in another
meta-analysis of 7 randomized trial of 40,233 patientsusing individual-patient data.131 A J-shaped relationship
was observed between DBP and mortality in both treated
and untreated hypertensive subjects. There was also a J
curve for non-cardiovascular mortality in the treated group
(but not in the untreated subjects). It was concluded that
the increased risk for events observed in patients with low
BP was not related to antihypertensive treatment and was
not specific to BP-related events. Poor health conditions
leading to low BP and an increased risk for death probably
explain the J-curve phenomenon.131
2). Low patient number: The patient number in the lowest BP
group was generally small. In the INVSET host-hoc
analysis, there were only 234 of 22,576 patients, who
had SBP of 110 mmHg and only 176 patients had a DBP
of 60 mmHg.126 It would be difficult to draw conclu-
sions from these data due to skewed distribution attribut-
able to patient numbers.
6.2. Overall BP thresholds and targetsTable 10 shows the overall BP targets for various clinical
conditions. These values are also BP thresholds. Treatment
should be considered when BP readings, confirmed in the
office or by ABPM or HBPM, are higher than these values
(Please also see Fig. 1). The thresholds and targets for patients
with diabetes, CHD, and proteinuric CKD (special patient
groups) are 130/80 mmHg, lower than other patient groups,
and lower than those suggested in the 2013 ESH/ESC hyper-
tension guidelines10 and in the 2014 JNC report.11 The ratio-
nale for defining these thresholds and targets are described in
the following sections.6.3. Primary preventionIn patients aged less than 80 years of age, earlier hyper-
tension studies such as the Medical Research Council (MRC)
trial (age 35-64 years)132 and the Felodipine Event Reduction
(FEVER) trial (age 50-79 years)133 showed that a final SBP
<140 mmHg in the treatment group conferred a decreased
incidence of cardiovascular events in comparison to that in the
control group (138 mmHg versus 149 mmHg in the MRC
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respectively). Recently, the Studio Italiano Sugli Effetti
CARDIOvascolari del Controllo della Pressione Arteriosa
SIStolica (Cardio-Sis) trial (age  55 years) has shown that
patients with tight BP control (SBP ¼ 131.9 mmHg) had a
better secondary cardiovascular outcome than those with usual
BP control (SBP ¼ 135.6 mmHg).134 Subgroup analysis of
FEVER trials disclosed that a SBP <140 mmHg resulted in a
39% reduction in stroke in patients without previous cardio-
vascular disease and diabetes (p ¼ 0.0016), and a 44%
reduction of stroke in patients aged >65 years
(p ¼ 0.0001).135 Additional important information came from
a recent publication from the Atherosclerosis Risk in Com-
munities Study (ARIC).113 In patients with hypertension but
without CV disease at baseline, those with a treated BP in the
range of 120-139 mmHg had the lowest CV events compared
to those with a treated BP >140 mmHg, or a treated BP
<120 mmHg.113
In the Hypertension Optimal Treatment (HOT) trial, pa-
tients were randomized into 3 groups, aiming to achieve DBPs
80, 85, or 90 mmHg.136 The lowest risk of CV events
was observed at a DBP of 82.6 mmHg, while a decrease of
DBP below this level had no effect on the reduction of risk of
cardiovascular complications. The study did not demonstrate
any increase in cardiovascular events in the group of patients
with a DBP <70 mmHg.136
Recommendation
 For patients <80 years of age and without diabetes, CHD,
and proteinuric CKD, BP targets are <140/90 mmHg.
(COR IIa, LOE B)
6.4. Patients with diabetesIn a prospective observation study in the UK (UKPDS 36),
4,801 patients were followed up for 10 years.122 The incidence
of clinical complications was significantly associated with
SBP. Each 10 mm Hg decrease in mean SBP was associated
with 12% reductions in the risk of any complication related to
diabetes (p < 0.0001), 15% reduction in deaths related to
diabetes (p < 0.0001), 11% reduction in myocardial infarction
(p < 0.0001), and 13% reduction in micro-vascular compli-
cations (p < 0.0001). No threshold of risk was observed for
any end point. The risk of all diabetes-related macro- and
microvascular endpoints were lowest in those patients with a
SBP less than 120 mm Hg, without any J-curve
phenomenon.122
Several RCTs have been done to compare aggressive BP
lowering vs standard BP lowering in patients with type 2
diabetes. In the SANDS trial, an aggressive SBP lowering
strategy (<115 mmHg) was compared with a standard
strategy (<130 mmHg), and the final values of SBP were
117 vs 129 mmHg.137 There was a significant regression of
carotid intimal medial thickness and greater decrease in left
ventricular mass in the aggressive treatment group. How-
ever, clinical events did not differ significantly between
groups.137There were only 2 RCTs to prospectively evaluate CV
outcomes with more aggressive vs conventional BP lowering
in type 2 diabetes. In the UKPDS 38 trial, a tight control
strategy aiming at a BP of <150/85 mm Hg was compared
with less tight control strategy aiming at a BP of <180/
105 mm Hg in 1148 hypertensive patients with type 2 diabetes
(mean age 56, mean BP at entry 160/94 mm Hg).138 After a
median follow-up of 8.4 years, mean BP was significantly
reduced in the group assigned to tight BP control (144/82 mm
Hg) compared with the group assigned to less tight control
(154/87 mm Hg) (p < 0.0001). There was significant reduction
in almost all of the macro- and microvascular events: 24% in
diabetes-related end points (p ¼ 0.0046), 32% in deaths
related to diabetes (p ¼ 0.019), 44% in strokes (p ¼ 0.013),
and 37% in microvascular end points (p ¼ 0.0092).138 There
was also a non-significant reduction in all-cause mortality. In
the ACCORD trial, patients with type 2 diabetes were
randomly assigned to intensive therapy, targeting a SBP
<120 mmHg, or standard therapy, targeting a
SBP<140 mmHg.139 At 1 year, the mean SBP was
119.3 mmHg in the intensive-therapy group and 133.5 mmHg
in the standard-therapy group. After a mean follow-up of 4.7
years, the annual rate of the primary outcome was 1.87% in
the intensive-therapy group and 2.09% in the standard-therapy
group (hazard ratio with intensive therapy, 0.88; p ¼ 0.20).139
Non-fatal myocardial infarction was decreased by 13% in the
intensive-therapy group (p ¼ 0.25). Though there was no
significant difference in total mortality, the annual rate of
stroke, a pre-specified secondary outcome, was decreased by
41% (p ¼ 0.01).139 The serious adverse events was, however,
more common in the intensive-therapy group (3.3% vs 1.3%,
p < 0.001).139 It should be known that the ACCORD trial was
comparing BP targets of <120 mmHg vs <140 mmHg, not
<130 mmHg vs 140 mmHg. While a SBP target <120 mmHg
was not supported by the ACCORD trial, one cannot deny the
intensive BP target of <120 mmHg was beneficial in reducing
stroke risk, which is the most important cardiovascular event
in East Asia. It should also be noted that there was no increase
in the risk of myocardial infarction. In fact, non-fatal
myocardial infarction was decreased by 13%, though not
statistically significant.139
The HOT trial is the most important RCT to test optimal
DBP in hypertensive patients. A total of 18,790 hypertensive
patients from 26 countries, with a DBP between 100 mm Hg
and 115 mm Hg (mean 105 mm Hg), were randomly assigned
to 3 target DBP groups: <90, <85, and <80 mmHg.136 The
lowest incidence of major cardiovascular events occurred at a
mean achieved DBP of 82.6 mmHg. Further reduction below
this level was safe. In a subgroup analysis of patients with
diabetes, there was a 51% reduction in major cardiovascular
events, including myocardial infarction, stroke, and CV
deaths, in target group <80 mm Hg compared with the group
<90 mmHg (p ¼ 0.005).136 The percentages of previous car-
diovascular diseases and risk factor were well balanced be-
tween the 3 groups. There was also a trend favoring a target of
<80 mmHg in reducing total mortality (relative risk ¼ 1.77 for
a target of <90 mmHg, p ¼ 0.068).136
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in patients with high CV risk mainly came from post-hoc ana-
lyses of several RCTs, including INVEST, LIFE, ONTARGET,
etc.120, 127, 140 The INVEST trial was designed to compare
mortality and morbidity outcomes in patients with hypertension
and CHD treated with calcium antagonist strategy or a non-
calcium antagonist strategy.141 The result showed that the
verapamil-trandolapril-based strategy was as clinically effec-
tive as the atenolol-hydrochlorothiazide-based strategy.141
Seven years after the original publication, investigators of the
INVEST trial reported a post-hoc analysis of the results of
diabetic patients in the original INVEST trial.120 Patients were
categorized as having tight control if they could maintain their
SBP< 130 mm Hg; usual control if it ranged from 130-
139 mmHg; and uncontrolled if it was140 mmHg. Patients in
the uncontrolled group had a significantly higher cardiovascular
event rate than the usual-control group (adjusted hazard ratio
1.46; p < 0.001). However, little difference existed between
those with tight control and those with usual control (p¼ 0.24).
The all-cause mortality rate did not show significant difference
either (p¼ 0.06), except when extended follow-upwas included
(HR ¼ 1.15; p ¼ 0.04). One should realize that this is an
observational subgroup analysis. The baseline CV diseases and
risk factors were un-balanced, and more common in the tight
control group compared to the usual-control group (e.g. left
ventricular hypertrophy 26% vs 22%; heart failure 8.8% vs
6.8%, smoking 48% vs 45%, and renal impairment 3.5% vs
2.4%; all p < 0.05). These measurable and other un-measurable
confoundersmight explainwhy ”lower-is-worse”.130 In fact, the
rates of fatal- and non-fatal myocardial infarction, and fatal- and
non-fatal stroke were still numerically lower in the tight control
group.120 Similar controversial observations were reported in
the post-hoc analyses in the LIFE and the ONTARGET tri-
als.127, 140 Disproving a target of <130 mmHg can only be
achieved by an RCT randomizing patients into different target
SBP, including <130 mmHg, to balance the baseline co-mor-
bidities and CV risk factors.
Several meta-analyses did support lower SBP targets for
patients with diabetes.142-144 It has been consistently shown in
these meta-analyses that with a more intensive lowering of
SBP to <130 mmHg, there was a significant decrease in stroke
and nephropathy, and a non-significant decrease in myocardial
infarction.143, 144 The recent report from the Cochrane Data-
base of Systematic Reviews did not support BP targets lower
than the standard targets in people with elevated BP and dia-
betes.145 Using tight SBP control to <130 mmHg was a major
contributor in reducing microalbuminuria in a Taiwanese
trial146 and in reducing ESRD and death in a Hong Kong
trial.147 In a recent report from National Survey of Diabetes
Health Promotion Institutes in Taiwan, using SBP<130 mmHg
as a BP target,148 the mortality rate in diabetics in Taiwan
decreased in the recent decade.149
The BP target for diabetes is probably the most controversial
issue in the management of hypertension. The 2013 ESH/ESC
hypertension guidelines,10 the 2014 JNC report,11 and the hy-
pertension guidelines of the American Society of Hypertension/
International Society of Hypertension150 all suggested aloosening of the target BP to <140/90 mmHg for diabetes.
Standards of Medical Care in Diabetes-2014, proposed by the
American Diabetes Association, suggested SBP targets of
<140/80 mmHg, but a SBP target <130 mmHg may be appro-
priate for certain individuals, such as younger patients, if it can
be achieved without undue treatment burden.151 Based onmeta-
analyses and the status of diabetes control in Taiwan, we set BP
targets of <130/80 mmHg in this guideline, similar to recent
hypertension guidelines from the Japanese Society of Hyper-
tension,152 the Global Guideline for Type 2 Diabetes from In-
ternational Diabetes Federation Guideline Development
Group,153 and the 2014 Canadian Hypertension Guidelines.154
Recommendation
 For patients with diabetes, BP targets are <130/80 mmHg.
(COR I, LOE B)
6.5. Patients with coronary heart diseaseA large body of evidence suggests that the coexistence of
hypertension and CHD has a substantial negative impact on a
patient's clinical profile and prognosis. The report of the
INTERHEART study involving 52 countries showed that
compared with diabetes, hypertension resulted in a higher risk
of acute myocardial infarction.155 Hypertension accelerates
the development and progression of atherosclerosis. Sustained
elevation of BP can destabilize vascular lesions and precipitate
acute coronary events. High BP per se can cause myocardial
ischemia in the absence of CHD. Lowering both systolic and
diastolic BP reduces ischemia and prevents adverse cardio-
vascular events in patients with CHD, partly by reducing
myocardial oxygen demand. The overall aims of treating hy-
pertension in patients with CHD are to lower BP, reduce
ischemia, and prevent cardiovascular events and death.
There has been no trial prospectively evaluating and
comparing different BP targets in patients with CHD. Three
large RCTs (HOPE, EUROPA, and PEACE) have been done
to evaluate the effects of ACE inhibitors versus placebo in
CHD.156-158 Re-analysis of these trials provided some clues
for determining BP targets in CHD patients. Baseline BP of all
these 3 trials were in the range of prehypertension (139/79,
137/82, and 133/78 mmHg for HOPE, EUROPA, and PEACE,
respectively).156-158 The final BP values were 136/76, 132/80,
and 129/74 mmHg, respectively. Primary endpoints decreased
by 22% in the HOPE trial (p < 0.001), 20% in the EUROPA
trial (p ¼ 0.0003), and 4% in the PEACE trial (p > 0.05). No
J-curve phenomenon was observed. A combined analysis of
these 3 trials indicated that ACE inhibitors significantly
reduced all-cause mortality, non-fatal MI, and all stroke in
patients with CHD, and no J-curve was found.159 In the
CAMELOT trial testing amlodipine and enalapril versus pla-
cebo in patients with CHD, BP was decreased from a baseline
of 129/78 mmHg to 124/75 mmHg (all in the prehypertension
range).160 Primary endpoints was decreased by 31%
(p ¼ 0.003) in the amlodipine group.160 In a sub-study of
CAMELOT using intra-vascular ultrasound, patients with final
BP 140/90 mmHg had a significant increase in atheroma
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89 mmHg had no major change in atheroma volume. Inter-
estingly, those with a final BP in the normal BP range (<120/
80 mmHg) had a significant decrease in atheroma volume.161
Finally, in the COURAGE trial which randomized patients
with stable CHD, optimal medical therapy alone was
compared to optimal medical therapy plus percutaneous cor-
onary intervention (PCI) in normotensive patients (mean
baseline BP 130/74 mmHg).162 The optimal medical therapy
regimen included long-acting beta blockers, calcium channel
blockers (CCBs), and ACE inhibitor or ARB. The final BP
was 122/70 mmHg. Interestingly, the addition of PCI to
optimal medical therapy as an initial management strategy did
not reduce the risk of death or myocardial infarction.162 This
study confirmed that, in the era of bare metal stent, optimal
medical therapy including aggressive BP-lowering is as
effective as PCI in the treatment of patients with stable CHD.
Three important meta-analyses supported aggressive BP
lowering in patients with CHD. One meta-analysis of 15
RCTs, enrolling 66,504 participants with 276,328 patient-
years of follow-up, has shown that in subjects with CHD a
target SBP goal <130 mm Hg was associated with a signifi-
cant decrease in heart failure (27%) and stroke (18%),
together with a modest decrease in myocardial infarction and
angina, when compared with a goal <140 mmHg.163 Another
meta-analysis of 25 trials consisted of 64,162 patients with
history of cardiovascular diseases and a pre-treatment BP
<140/90 mmHg.164 Antihypertensive medications resulted in a
23% reduction in stroke, 20% reduction in myocardial
infarction, 29% reduction in heart failure, 15% reduction in
composite cardiovascular endpoints, 17% reduction in car-
diovascular mortality, and a 13% reduction in total mortality
(all p < 0.05). The most important meta-analysis supporting
aggressive BP lowering consisted of 464,000 subjects from
147 trials.165 It shows that for a given BP reduction by using
BP-lowering drugs the risk of CHD and stroke decreased by a
constant proportion irrespective of pretreatment BP and the
presence or absence of existing cardiovascular diseases.165 In
patients with a pretreatment DBP of 70-74 mmHg or SBP of
110-119 mmHg, anti-hypertensive drugs decreased the risk of
stroke and CHD, without any evidence of J-curve phenome-
non.165 A meta-analysis from the BP Lowering Treatment
Trialists' Collaboration (BPLTTC) also supported a similar
concept.166 In the recent re-analysis using data from the
INVEST trial, switching the BP target to a higher 150 mmHg,
suggested by the recent 2014 JNC report,11 was associated
with worse outcomes in patients with CHD.167
Recommendation
 For patients with a history of CHD, BP targets are <130/
80 mmHg. (COR I, LOE B)6.6. Patients with a history of strokeThe decision to treat hypertension in patients with a history
of stroke depends on the disease type and stage. The appropriatetreatment of hypertension in acute stroke remains controversial.
During the initial 24 hours in the acute stage of ischemic stroke,
antihypertensive drugs should not be used unless BP is >220/
120 mmHg.168 In the CATIS trial, patients with acute ischemic
stroke within 2 days, controlling BP with a target of <140/
90 mmHg at 7 days did not reduce the likelihood of death and
major disability at 14 days or hospital discharge.169 But in pa-
tients with recent lacunar stroke, a tight control of BP to
<130 mmHg reduced intracerebral hemorrhage compared to a
target of 130e149 mmHg, though there was no differences in
the rate of all stroke.170 In patients who are eligible for acute
reperfusion therapy, a BP level >185/110 mmHg should be
lowered to <180/105 mmHg before reperfusion therapy.171
In patients with hemorrhagic stroke, cumulating evidence
indicated that early BP lowering could reduce hematoma
expansion. Therefore, in patients with acute hemorrhagic
stroke, a SBP >180 mmHg can be decreased to
<140 mmHg.172 Most patients can receive antihypertensive
treatment when BP is >140/90 mmHg after several days in the
convalescent state.
For long-term hypertension control in patients with a his-
tory of stroke, BP control to the target level is the first
consideration. There were 3 trials that enrolled patients who
had experienced previous stroke.156, 173, 174 Aggressive
BP lowering reduced stroke and CV events, but the achieved
BP was higher than 130 mmHg. The target BP level is
<140/90 mmHg for patients with stable cerebrovascular dis-
ease.173-175
Recommendations
 For patients with a history of stroke, BP targets are <140/
90 mmHg. (COR I, LOE A)
 During the initial 24 hours in the acute stage of ischemic
stroke, antihypertensive drugs should not be used unless
BP is >220/120 mmHg. (COR I, LOE C)
 In patients who are eligible for acute reperfusion therapy, a
BP level >185/110 mmHg should be lowered to <180/
105 mmHg before reperfusion therapy. (COR I, LOE B)
 In patients with acute hemorrhagic stroke, an SBP
>180 mmHg can be decreased to <140 mmHg. (COR IIa,
LOE B)
 After several days in the convalescent state of hemorrhagic
stroke, most patients can receive antihypertensive treat-
ment when BP is >140/90 mmHg. (COR I, LOE C)
6.7. Patients with chronic kidney disease6.7.1. Threshold and target for patients with CKD in stages
2 - 4
Although CKD is the most common cause of secondary hy-
pertension, hypertension can impair kidney function as well. If
combined with proteinuria,176 hypertensionmay result in a more
rapid deterioration of kidney function in patients with CKD.177
Patients with lower eGFR and higher albuminuria have an
increased risks of all-cause mortality, CV mortality, and ESRD,
though the risk seems to be higher in women than inmen.178 The
stages of CKD have been defined and widely adopted.179
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target of<130/80mmHg for patients with CKD,with or without
diabetes.9, 115, 180 However, there has been scant evidence to
date that supported this target. In 3 trials enrolling patients with
non-diabetic CKD, patients who were randomized to a target
SBP of 125e130mmHg did not have a reduced risk of ESRD or
all-cause death, compared with patients who were randomized
to a target BP of <140 mmHg.181-183 Meta-analyses did not
support a target of <130/80 mmHg, either.184, 185 A recent
analysis from a nationwide cohort of US veterans with prevalent
CKD, using stricter SBP control to <120 mmHg, and compared
to a target of 120e139 mmHg, was associated with higher all-
cause mortality.186 For patients with proteinuria, post-hoc
analysis from MDRD indicated that the benefit of a lower BP
target (<130/80 mm Hg) was limited to renal outcomes.187 The
results regarding proteinuria were not repeated in the primary
analyses in either the AASK or REIN-2 trials.182, 183
Regarding the relation between BP control and diabetic
nephropathy, three large trials showed that ARBs prevented
the development of clinical proteinuria or delayed the pro-
gression of nephropathy in type 2 diabetes.188-190 But the reno-
protective effect was independent of the blood pressure
lowering effect, and the achieved SBP was >130 mmHg. In
diabetic patients with normal eGFR,139 more intensive
lowering of BP (119/67 vs. 134/73 mmHg) was associated
with significant impairment of renal function.
Recommendations
 For patients with CKD stages 2 e 4 without albuminuria,
BP targets are <140/90 mmHg. (COR I, LOE A)
 In patients with CKD stages 2 e 4, but with albuminuria,
BP targets are <130/80 mmHg. (COR IIb, LOE C)
6.7.2. Threshold and target for patients with ESRD (stage 5
CKD)
In patients with ESRD, who have undergone multiple sur-
gical procedures for vascular access in both arms, BP should be
measured in the thighs or legs. Among patients receiving
maintenance hemodialysis, observational studies have demon-
strated a U-shaped relationship between BP and mortality.191,
192 One study suggested that the increased mortality associ-
ated with low SBP was more pronounced among older patients
and patients with diabetes.193 There have been no RCTs to
examine the BP targets for patients receiving dialysis. In gen-
eral, BP goals should be individualized, based upon patients'
cardiac and neurologic status, comorbidities, age, and other
clinical conditions. The National Kidney Foundation K/DOQI
guidelines suggested that pre-dialysis and post-dialysis BPs
should be <140/90 and <130/80 mmHg, respectively.194, 195
Recommendations
 For patients with CKD stage 5, BP targets are <150/
90 mmHg. (COR I, LOE C)
 For patients receiving maintenance dialysis, BP targets are
<140/90 mmHg before dialysis, and <130/80 mmHg after
dialysis, respectively. (COR IIb, LOE C)6.8. Elderly patientsFor patients over 60 years of age, 3 RCTs (SHEP, Syst-Eur,
and Syst-China) randomized patients with isolated systolic
hypertension (ISH) (baseline SBP >160 mmHg and DBP<90
or 95 mmHg).123-125 Patients received chlorthalidone (SHEP)
or nitrendipine (Syst-Eur and Syst-China) and achieved lower
BP than those patients who took a placebo (143/68 vs 155/
72 mmHg in the SHEP trial; 151/79 vs 162/85 mmHg in the
Syst-Eur trial; and 151/81 vs 159/84 mmHg in the Syst-China
trial).123-125 These 3 trials consistently demonstrated a
significantly lower risk of stroke and other cardiovascular
events in treated patients compared to placebo.123-125 How-
ever, 2 recent Japanese trials produced different findings.196,
197 The Japanese Trial to Assess Optimal Systolic Blood
Pressure in Elderly Hypertensive Patients (JATOS) trial ran-
domized patients 65-85 years of age.196 The achieved BP in
the strict treatment group was lower than the mild treatment
group (135.9/74.8 vs 145.6/78.1 mmHg), but there was no
difference in cardiovascular outcomes. The Valsartan in
Elderly Isolated Systolic Hypertension (VALISH) trial ran-
domized patients from 70 to 84 years of age.197 In that trial,
strict BP control to 136.6/74.8 mmHg did not decrease CV
events compared to moderate control group (142.0/
76.5 mmHg). However, the patients enrolled in these 2 trials
had very low event rate (1.1e1.2%/year in JATOS,
0.82e0.85%/year in VALISH), and might not represent real
world conditions.196, 197 Therefore, the 2009 Japanese HT
guidelines adopted a target of <140/90 mmHg in the
elderly,198 instead of <150/90 mmHg which was suggested by
these 2 trials.196, 197 Furthermore, a subgroup analysis of the
elderly patients in the FEVER trial in China showed a
reduction of CV events by lowering SBP below 140 mmHg,
compared to 145 mmHg.135
For patients aged 80 years of age, a subgroup meta-
analysis of RCTs showed a significant reduction (34%) in
stroke, with an achieved SBP <150 mmHg.199 Rates of major
cardiovascular events and heart failure were also significantly
decreased, by 22% and 39%, respectively.199 However, there
was no treatment benefit for cardiovascular death, and a non-
significant increase of 6% (5 to 18%) in all-cause mortal-
ity.199 Recently, the Hypertension in the Very Elderly Trial
(HYVET) randomized elderly patients 80 years of age and a
baseline BP of 173.0/90.8 mmHg. The investigators aimed to
achieve a target BP of 150/80 mmHg, using diuretic versus
placebo, while ACE inhibitors could be added when
required.200 The final achieved BP was 144/78 mmHg in the
treatment group, significantly lower than that in the control
group (161/84 mmHg). The trial was prematurely stopped due
to a significant decrease in total mortality in the treatment
group (21%, p ¼ 0.02).200 There were also a 30% reduction
in the rate of fatal or nonfatal stroke (p ¼ 0.06), a 39%
reduction in the rate of death from stroke (p ¼ 0.05), a 23%
reduction in the rate of death from cardiovascular causes
(p ¼ 0.06), and a 64% reduction in the rate of heart failure
(p < 0.001).200 Fewer serious adverse events were reported in
the active-treatment group.200
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 For patients with an age 80 years, irrespectively of other
clinical conditions, BP targets are <150/90 mmHg. (COR
IIa, LOE B)
 For patients with an age <80 years and without diabetes,
CHD, and proteinuric CKD, BP targets are <140/
90 mmHg. (COR IIa, LOE B)6.9. Patients receiving antithrombotic therapy for stroke
preventionHypertension is closely related to the risk of hemorrhagic
stroke.201 In patients with both hypertension and atrial fibril-
lation, controlling BP is important if oral anticoagulants are to
be used. Asians are especially vulnerable to oral vitamin-K
antagonists for the treatment of atrial fibrillation.202 While
anti-coagulation was less intensively controlled and higher
percentages of patients in Asians had international normalized
ratio (INR) in the range of <2.0 when compared to that in
Westerns, higher bleeding risk, especially higher intra-cranial
hemorrhage, was observed in Asians in all recent RCTs.203 In
a prospective, multicenter, observational cohort study (BAT
Study) of 4009 Japanese patients taking oral antithrombotic
agents for cardiovascular or cerebrovascular diseases, the
optimal cutoff BP level to predict impending risk of intra-
cranial hemorrhage was 130/81 mmHg.204 Lower SBP
reduced intra-cranial hemorrhage in the PROGRESS trial, in
which the lowest risk of intracranial bleeding was observed in
participants with the lowest follow-up SBP (median, 113 mm
Hg).205 In most of the RCTs comparing non-vitamin K
dependent oral anticoagulants (NOACs) versus warfarin, the
baseline BP was well controlled (131/77 mmHg in the RE-LY
trial, 131/80 mmHg in the ROCKET AF trial, and 130 mmHg
in the ARISTOTLE trial).206-208 So, predictors for intra-cranial
hemorrhage did not include SBP, except in the ARISTOTLETable 11
Life style modification for managing hypertension (S-ABCDE).
Changes Recommendation
Sodium restriction 2.0e4.0 gm/day
Alcohol limitation Men: <30 gm/day ethanol
Women: <20 gm/day ethanol
Body weight reduction BMI: 22.5e25.0
Cigarette smoking cessation Complete abstinence
Diet adaptation DASH diet: rich in fruits and
vegetables (8e10 servings/
day), rich in low-fat dairy
products (2e3 servings/day),
and reduced in saturated fat
and cholesterol
Exercise adoption Aerobic, at least 40 minutes/
day, and at least 3-4 days/
week
BMI ¼ body mass index; COR ¼ class of recommendation; DASH ¼ Dietary App
pressure. (Modified from Chiang et al.9 with permission.)trial in which the hazard ratio was 1.17 for every 10 mmHg
increase in DBP (p < 0.05).207
Recommendation
 For patients receiving antithrombotic therapy for stroke
prevention, BP targets are <130/80 mmHg. (COR I,
LOE B)
7. Treatment
Treatment of hypertension should include non-
pharmacological management and drug therapy. LSM is the
essential component of non-pharmacological management.
LSM is the initial treatment for the first 3 months in patients
with uncomplicated stage 1 hypertension, or those with dia-
betes, CHD, or proteinuric CKD (special patient group) whose
BP is between 130-149/80-89 mmHg. If BP is still above
target, drug therapy should be initiated. For patients with stage
2 hypertension or above, including special patient group
whose BP is above 150/90 mmHg, LSM should be combined
with drug therapy. In general, LSM should be regarded as a
complement to drug therapy rather than an alternative.1507.1. Life style modificationLSM is an essential part in the prevention and management
of hypertension.209 It is generally believed that the BP-
lowering effect of LSM is equivalent to drug mono-
therapy.210 If applied appropriately, LSM can delay drug
therapy in patients with stage 1 hypertension, allowing
reduction in the number and doses of anti-hypertension drugs.
The major limitation of LSM lies in the poor consistency and
adherence.211 LSM can be summarized as S-ABCDE: Sodium
restriction, Alcohol limitation, Body weight reduction, Ciga-
rette smoke cessation, Diet adaptation, and Exercise adoption
(Table 11).Expected benefits in SBP
reduction
COR LOE
2.5 mmHg/1 gm sodium
reduction
I B
2e4 mmHg I B
1 mmHg/per 1 kg reduction I B
No independent effect I C
10e12 mmHg I A
3e7 mmHg I A
roaches to Stop Hypertension; LOE ¼ level of evidence; SBP ¼ systolic blood
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The role of sodium in cardiovascular diseases has recently
become very controversial. For BP control, it is generally
agreed that higher sodium intake increases BP. In the recent
PURE study of 102,216 adults from 18 countries, the 24-hour
sodium and potassium excretion were measured, using a single
fasting morning urine specimen.212 It was shown that for each
1-gram (gm) increment in estimated sodium excretion, SBP
increased by 2.11 mmHg, and DBP by 0.78 mmHg.212 The
slope of association was steeper for persons with hypertension
(2.49 mmHg per gm) than for those without hypertension
(1.30 mmHg per gm, p < 0.001 for interaction) and was
steeper with increased age (2.97 mmHg per gm at >55 years of
age, 2.43 mmHg per gm at 45 to 55 years of age, and
1.96 mmHg per gm at <45 years of age; p < 0.001 for
interaction). Potassium excretion was inversely associated
with SBP, with a steeper slope of association for persons with
hypertension than for those without it (p < 0.001) and a
steeper slope with increased age (p < 0.001).212 The PURE
study is the most robust one to confirm that increased intake of
sodium is related to an increase in BP. Sodium restriction is
especially effective in patients with resistant hypertension213
and in patients with metabolic syndrome in Asia.214
Intensive lowering of sodium intake has been proposed by
major scientific societies. In the recent 2013 AHA/ACC
Guideline on Lifestyle Management to Reduce Cardiovascular
Risk,215 it was proposed that reducing sodium intake that
achieved a mean 24-hour urinary sodium excretion of
approximately 2.4 gms/day, relative to approximately 3.3 gms/
day, lowers BP by 2/1 mm Hg, and reducing sodium intake
that achieved a mean 24-hour urinary sodium excretion of
approximately 1.5 gms/day lowers BP by 7/3 mm Hg.215 This
statement was supported by a recent report from the
NUTRICODE investigators.216 The NUTRICODE in-
vestigators collected data from surveys on sodium intake as
determined by urinary excretion and diet in persons from 66
countries, and quantified the global consumption of sodium.
The effects of sodium on BP were calculated from data in a
new meta-analysis of 107 randomized interventions.216 The
effects of BP on cardiovascular mortality were calculated from
a meta-analysis of cohorts.216 It was found that in 2010 the
estimated mean level of global sodium consumption was 3.95
gms per day. Globally, 1.65 million deaths from cardiovascular
causes per annum were attributed to sodium intake above the
reference level 2.0 gms of sodium per day.216
A contradictory report came from a recent publication from
another contemporary report from PURE investigators.217 The
PURE investigators obtained morning fasting urine samples
from 101,945 persons in 17 countries, and found the mean
estimated sodium excretion was 4.93 gms per day. As
compared with an estimated sodium excretion of 4.00 to 5.99
gms per day (reference range), a higher estimated sodium
excretion (7.00 gms per day) was associated with an
increased risk of the composite outcome (death and major CV
events) (odds ratio, 1.15; p < 0.05).217 Interestingly, as
compared with the reference range, an estimated sodium
excretion that was below 3.00 gms per day was also associatedwith an increased risk of the composite outcome (odds ratio,
1.27; p < 0.05).217 Thus, there is a J-shape association be-
tween sodium intake and cardiovascular disease or death, and
an estimated sodium intake between 3 gms per day and 6 gms
per day was associated with a lower risk of death and car-
diovascular events than either a higher or lower estimated level
of intake.217 This J-shape association has been reported in
other studies,218 and a recent meta-analysis.219 In fact, in a
prospective cohort study in Taiwan a significant J-shape
relationship between urinary sodium excretion and the risk of
hypertension has also been observed, and the nadir of the J-
shape was around 100 mmol (2.4 gms)/day.220
The most important long term intervention trial for effects
of dietary sodium reduction on cardiovascular disease out-
comes came from TOHP I and TOHP II trials.221 In these
trials, the risk of cardiovascular event was 30% lower among
those in the intervention group.221 The final level of achieved
daily sodium excretion (or intake) was 2.3 gms/day for TOHP
I and 3.2 gms/day for TOHP II.221 Thus, the optimal target for
sodium restriction is still controversial, but an optimal level
will be around 2.0-4.0 gms/day. Too aggressive sodium re-
striction to <2.0 gms/day should be avoided. Supplemental
calcium, potassium, or magnesium have been proposed to
lower BP, but data are not entirely consistent.222
Recommendations
 For controlling hypertension, the optimal daily sodium
consumption is 2.0-4.0 gms/day. (COR I, LOE B)
 Too aggressive sodium restriction to <2 gms/day may be
harmful. (COR III, LOE B)
7.1.2. Alcohol limitation
Excessive drinking is associatedwith highBP.223 In thePATHS
trial investigating the effects of an alcohol treatment program on
BP, there was a 1.2/0.7 mmHg greater reduction for every 1.3
drink/day difference.224 In ameta-analysis of 15RCTswith a total
of 2,234 participants, alcohol reduction was associated with a
significant reduction of 3.31 mmHg in SBP and 2.04 mmHg in
DBP.225 It is generally agreed that alcohol intake should be limited
to <30 gms/d in men and <20 gms/d in women.222
Recommendation
 For controlling hypertension, the daily intake of alcohol
should be limited to <30 gms/d in men and <20 gms/d in
women. (COR I, LOE B)
7.1.3. Body weight reduction
Obesity is related to increased cardiovascular mortality. A
meta-analysis of 25 RCTs with 4,874 participants was per-
formed to estimate the effect of weight reduction on BP.226 A
net weight reduction of 5.1 kilogram (kg) reduced SBP by
4.44 mmHg and DBP by 3.57 mmHg.226 SBP was reduced by
1.05 mmHg, and DBP by 0.92 mmHg per kg of weight loss.226
The relationship of BMI with overall mortality shows a U-
shape phenomenon. In the Prospective Studies Collaboration
of 57 prospective studies with 894,576 participants, mostly in
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the range of 22.5-25.0 kg/m2.227 Similarly, in a prospective
cohort study of 224,064 Chinese men followed up for 15
years, the association between BMI and all-cause mortality
was U-shaped with the lowest mortality at 22.5-25.0 kg/m2.228
Interestingly, an intensive lifestyle intervention focusing on
weight loss did not reduce the rate of cardiovascular events in
overweight or obese adults with type 2 diabetes.229
Recommendation
 For controlling hypertension, the ideal BMI is 22.5-
25.0/m2. (COR I, LOE B)
7.1.4. Cigarette smoke cessation
Stopping smoking did not reduce BP,230 though smoking
may cause an acute increase in heart rate and BP. Smoking is
the most important preventable risk factor in myocardial
infarction, and smoking cessation is one of the most important
causes of reduced stroke death in Taiwan in the recent
decade.231 Therefore, cessation in cigarette smoking should be
an integral part of the whole LSM in the management of
hypertension.
Recommendation
 For the purpose of reducing overall cardiovascular risk,
cessation of cigarette smoking is an integral part of LSM.
(COR I, LOE C)
7.1.5. Diet adaptation
TheDASH (DietaryApproaches to StopHypertension) diet is
high in vegetables, fruits, low-fat dairy products, whole grains,
poultry, fish, and nuts; it is low in sweets, sugar-sweetened
beverages, and red meats.232 The DASH diet reduced SBP and
DBP by 11.4 and 5.5 mmHg, respectively, in hypertensive per-
sons.232 The combination of DASH and low sodium diet could
reduce the SBP by 11.5 mmHg compared with the combination
of control and high sodium diet.233 The combination of DASH
diet and a weight management programwas even more effective
than the usual diet controls, in which BP was reduced by 16.1/
9.9 mmHg.234 Better adherence to the DASH diet was signifi-
cantly associated with lower CHD and stroke.235, 236
Recommendation
 For controlling hypertension and reducing overall cardio-
vascular risk, the DASH diet should be an integral part of
LSM. (COR I, LOE A)
7.1.6. Exercise adoption
In two meta-analyses, aerobic exercise was associated with
a significant reduction in mean SBP (3.8 and 6.9 mmHg,
respectively) and DBP (2.6 and 4.9 mmHg, respec-
tively).237, 238 Typical interventions shown to be effective in
lowering BP include aerobic physical activity of, on average,
at least 12 weeks duration, 3 to 4 sessions per week, lasting on
average 40 minutes/session, and involving moderate-to-
vigorous intensity physical activity.215Recommendation
 For controlling hypertension, regular aerobic exercise
should be an integral part of LSM. (COR I, LOE A)7.2. Principles of drug therapyDrug therapy should be initiated in patients with stage 1
hypertension if their BP is still above targets, after 3-month
LSM. For patients in the special patient group (diabetes,
CHD, or proteinuric CKD), drug therapy should be initiated if
BP is still >130/80 mmHg after 3-month LSM. For patients
with stage 2 hypertension or above, including special patient
group whose BP is above 150/90 mmHg, drug therapy should
be started, concomitant with LSM as initial management.
The main benefits of antihypertensive agents are derived
from lowering of BP per se, and are generally independent of
classes of drugs.239, 240 Substantial data has come from the
largest meta-analysis of 147 trials consisting of 958,000 peo-
ple.165 With the exception of the extra protective effect of
beta-blockers given shortly after a myocardial infarction and
the additional effect of CCBs in preventing stroke, all classes
of BP lowering drugs have similar effects in reducing CHD
events and stroke for a given reduction in BP. Pleiotropic ef-
fects were not observed.165 For every 10 mmHg difference in
SBP or every 5 mmHg difference in DBP compared with
placebo, a 22% reduction in CHD and a 41% reduction in
stroke were observed.165 In a recent meta-analysis of 18 trials
of 23,215 Asian patients, a 10 mmHg reduction in SBP was
associated with a 39.5% reduction in composite CVendpoints,
and a 30% reduction in stroke, regardless of drug class.241
Some RCTs included patients with specific diseases or
conditions, so it has been proposed that one drug or certain
combinations of drugs might be superior to other drugs or
other combinations in reducing stroke,242 end-stage renal
disease,190 or cardiovascular events.243 244 Some recommen-
dations for different clinical conditions were shown in
Table 12. Because more than 70% of patients require more
than 1 drug to reach targets, it seems more important to choose
appropriate combination of drugs, instead of chasing a single
drug in our daily practice.
Based on data from a meta-analysis of 354 randomized,
double-blind, placebo-control trials comprising 40,000 drug-
treated patients and 16,000 placebo-treated patients,245 we
have proposed a “Rule of 10” (Fig. 3) and a “Rule of 5”
(Fig. 4) to predict the reduction in SBP and DBP, respectively,
from mono-therapy or combination therapy.9 These rules can
be used to predict how many drugs are needed to achieve BP
targets. With a standard dose of any one of the 5 major classes
of anti-hypertensive agents, one can anticipate approximately
a 10-mmHg decrease in SBP (Rule of 10) (Fig. 3, Panel A) and
a 5-mmHg decrease in DBP (Rule of 5) (Fig. 4, Panel A) (all
after placebo-subtraction), when the baseline pre-treatment BP
is 154/97 mmHg.245 The efficacy of BP lowering depends on
the pre-treatment BP. For every 10 mmHg above 154 mmHg in
baseline SBP or above 97 in the DBP mmHg, a further
decrease of 1.0 mmHg in SBP and 1.1 mmHg in DBP can be
observed. For example, one can anticipate a 11-mmHg
Table 12
Recommended drugs.
Clinical conditions Drugs
Target organ damage
Left ventricular hypertrophy ARB
Microalbuminuria ACEI, ARB
Asymptomatic atherosclerosis CCB
Clinical events
History of myocardial infarction BB, ACEI, ARB
Coronary Heart Disease BB, ACEI, ARB, CCB (long-acting)
Heart failure Thiazide diuretic, loop diuretic, BB,
ACEI, ARB, MRA
Stroke ACEI, ARB, Thiazide diuretic, CCB,
Chronic kidney disease ACEI, ARB, loop diuretic
Peripheral artery disease CCB
Diabetes mellitus ACEI, ARB, DRI
Associated conditions
Isolated systolic hypertension Thiazide diuretic, CCB, ARB
Metabolic syndrome ACEI,ARB
Benign prostate hypertrophy Alpha-blocker
ACEI ¼ angiotensin converting enzyme inhibitor; ARB ¼ angiotensin re-
ceptor blocker; BB ¼ beta blocker; CCB ¼ calcium channel blocker; DRI ¼
direct renin inhibitor; MRA ¼ mineralocorticoid receptor antagonist. (Modi-
fied from Chiang et al.9 with permission.)
Fig. 3. Rule of 10. Panel A. Comparison of effects of incremental doses of 5
classes of anti-hypertension drugs on reducing systolic blood pressure (SBP) at
a baseline SBP of 154 mmHg. On average, there is a 10-mmHg decrease in
SBP by a standard dose of any kind of the 5 classes of drugs (Rule of 10).
Doubling the dose of any drug brings out only a 2-mmHg incremental decrease
in SBP. Panel B. Combination of drugs from different classes is more effective
in reducing SBP than increasing doses of the same drug. The combination of 2
drugs from different classes decreases SBP by 20 mmHg (10 þ 10 ¼ 20);
whereas doubling doses decreased SBP further by 2 mmHg only
(10 þ 2 ¼ 12). To decrease SBP by 30 mmHg, 3 drugs of different classes are
generally needed. Data were modified from article by Laws et al.245
Fig. 4. Rule of 5. Panel A. Comparison of the effects of incremental doses of 5
classes of anti-hypertension drugs on reducing diastolic blood pressure (DBP)
at a baseline DBP of 97 mmHg. On average, there is a 5-mmHg decrease in
DBP by a standard dose of any kind of the 5 classes of drugs (Rule of 5).
Doubling the dose of any drug brings out only a 1-mmHg incremental decrease
in DBP. Panel B. Combination of drugs from different classes is more
effective in reducing DBP than increasing doses of the same drug. The
combination of 2 drugs from different classes decreases DBP by 10 mmHg
(5 þ 5 ¼ 10); whereas doubling doses decreased DBP further by 1 mmHg only
(5 þ 1 ¼ 6). To decrease DBP by 15 mmHg, 3 drugs of different classes are
generally needed. Data were modified from article by Laws et al.245
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treatment BP is 164/107 mmHg. When the doses of the
same drug were doubled, there was only a 2-mmHg incre-
mental decrease in SBP (Fig. 3, Panel A and B) and a 1-mmHg
incremental decrease in DBP (Fig. 4, Panel A and B).245
Preferably, when 2 drugs in standard doses but with different
mechanisms are taken together, the decrease in BP is the sum
of the decrease of the individual agents (approximately
20 mmHg in SBP and 10 mmHg in DBP) (Fig. 3 and 4, Panels
B).245, 246 Similarly, if a 30-mmHg decrease in SBP or a 15-
mmHg decrease in DBP is to be obtained, a 3-drug combi-
nation may be needed (Figs. 3 and 4, Panels B).245
When drug therapy is considered after a 3-month trial of
LSM or in patients with stage 2 hypertension or above, a
strategy called “PROCEED” is suggested.9 First, Previous
unfavorable experience of the individual patient with a given
class of antihypertensive drug should be carefully explored,
because adverse events are the most important cause of non-
adherence. Adverse events are inevitable, or even unpredict-
able, because they may have a psychological basis and are
frequently reported during placebo treatment. Great effort
should be advocated to limit drug-related side effects. Drug-
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beta-blockers, and CCBs, whereas there is little or no dose-
dependent increase in side effects with ACE inhibitors and
ARB.245 Second, Risk factors for an individual patient should
be identified. For example, diuretics and beta-blockers should
not be considered as first-line therapy in patients with meta-
bolic syndrome or glucose intolerance, unless strongly indi-
cated or used as an add-on therapy to reach target. Third,
Organ damage, even sub-clinical, or previously associated
cardiovascular conditions may favor certain classes of drugs or
certain combinations (Table 12). Fourth, Contraindications or
unfavorable conditions should be examined (Table 13). Fifth,
an Expert's or doctor's judgment is of paramount importance in
managing patients. Any guideline can only serve as reference
in treating individual patient. Sixth, Expenses or cost may be
taken in account. However, the cost issue should never pre-
dominate over efficacy, tolerability, and protection of the pa-
tient. Finally, Delivery and compliance issue is the key to
successful treatment of hypertension. WHO has estimated that
50e70% of patients did not take their antihypertensive drugs
as prescribed and has identified poor adherence as the most
important cause of uncontrolled hypertension. Physicians
should include patients as an essential part of the whole
treatment program in hypertension and communicate with
individual patients.
The optimal time for taking anti-hypertensive drugs has
been a matter of debate for decades. Morning administration
of antihypertensive drugs was routinely performed in the past.
However, it has been recently more common to switch to a
bedtime administration. In the MAPEC trial, 3344 subjects
were prospectively randomized to ingest all their prescribed
hypertension medications upon awakening or 1 of them at
bedtime, for a follow-up of 5.6 years.43 The nighttime BP was
more effectively decreased by bedtime administration of
drugs. More importantly, asleep BP was the most significantTable 13
Contraindications or unfavorable conditions.
Contraindications Unfavorable conditions
Thiazide diuretics Gout, hypokalemia,
hyponatremia, metabolic
syndrome, pregnancy
BB Bronchial asthma, sick
sinus syndrome, 2nd and
3rd degree AV block
Peripheral artery disease,
Metabolic syndrome
CCB (non-DHP) Sick sinus syndrome, 2nd
and 3rd degree AV block
Systolic heart failure
ACEI Bilateral renal artery
stenosis, pregnancy,
angioedema
Hyperkalemia
ARB Bilateral renal artery
stenosis, pregnancy
Hyperkalemia
DRI Bilateral renal artery
stenosis, pregnancy
Hyperkalemia
MRA Hyperkalemia
Alpha-blocker Systolic heart failure
ACEI ¼ angiotensin converting enzyme inhibitor; ARB ¼ angiotensin re-
ceptor blocker; BB ¼ beta blocker; CCB ¼ calcium channel blocker; DHP ¼
dihydropyridine; DRI ¼ direct renin inhibitor; MRA ¼ mineralocorticoid
receptor antagonist. (Modified from Chiang et al.9 with permission.)predictor of event-free survival. In fact, the same investigators
have demonstrated earlier that patients who took 1 anti-
hypertensive drug at bedtime showed a significant reduction
in the 24-hour mean of SBP and DBP.247 The reduction was
more prominent during nighttime. The diurnal/nocturnal BP
ratio was significantly increased and the prevalence of non-
dipping was reduced.247 This finding was supported by 2
studies using ARB at bedtime.248, 249 The nocturnal BP is
significantly better controlled by bedtime administration as
compared with morning administration, without any loss in
efficacy during diurnal active hours.250 Studies on surrogate
endpoints, such as urinary albumin excretion, also demon-
strated that switching the time that hypertensive drugs are
taken (from morning to evening) was beneficial in patients
with CKD.251, 252 In fact, the American Diabetes Association
has proposed the administration of one or more antihyper-
tensive medications at bedtime.151 Since nighttime BP has
been shown to be a more important predictor of cardiovascular
risk than diurnal mean values, the bedtime administration of
anti-hypertensive drugs may be a correct way to decrease
future cardiovascular events. Several classes of medications,
such as ACE inhibitors,156, 250 ARB,249 or CCB,124 have been
proven to be safe and effective for bed-time administration.
There has been no evidence supporting the use of diuretics or
beta-blockers at bedtime.
Another important issue is how soon we should control BP
to targets. Important information came from the VALUE
trial.253 The valsartan-based group had similar CVoutcomes as
the amlodipine-based group at the end of the trial. There were
3.8 mmHg differences in SBP at 3 months, and they were
higher in the valsartan-group. Except for heart failure admis-
sion, the primary endpoints, stroke, and all-cause death were
significantly higher in the valsartan group than in the amlo-
dipine group in the first 3 months.253 The BP differences
became insignificant after 3 months, and all the differences in
these CVendpoints did not show any difference thereafter. The
immediate responders, defined as those who could achieve a
10-mmHg decrease in the first month of treatment, had lower
CV events than non-immediate responders.254 Similar findings
were reported from the SCOPE trial.255 Patients in the placebo
group received placebo for the first 3 months, and eventually
had a higher incidence of non-fatal stroke compared with
patients in the treatment group who received candesartan
immediately after randomization.255 We therefore suggest it
appropriate to control BP to targets at 3 months, and prefer-
ably within 1 month, for high-risk patients.7.3. MonotherapyThere are 5 major classes of anti-hypertension drugs: di-
uretics, beta-blockers, CCBs, ACE inhibitors, and ARBs. As
previously mentioned, every kind of antihypertension drugs can
be used as the first line medications, per physician's discretion.
The NICE clinical guideline on hypertension from UK (http://
pathways.nice.org.uk/pathways/hypertension) has recently
abandoned the first-line use of diuretics and beta-blockers. The
2014 JNC report dismissed beta-blockers as first-line therapy.11
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all 5 major classes of drugs in their recommendations.10 There
are contraindications and unfavorable conditions when using
these different classes of drugs (Table 13).
7.3.1. Diuretics
7.3.1.1. Thiazides and thiazide-like diuretics. Thiazide di-
uretics and thiazide-like diuretics (e.g. indapamide, chlortha-
lidone, etc) remain essential in the treatment of hypertension.
The ALLHAT trial has confirmed the equivalent effect of
chlorthalidone in reducing CHD as compared to CCB and
ACE inhibitor.256 In fact, chlorthalidone is the best drug in
reducing heart failure in the ALLHAT trial.256 The efficacy of
thiazide diuretic in reducing heart failure has also been
confirmed in a large meta-analysis of 147 RCTs.165 When BP
cannot be controlled with ACE inhibitors or ARBs, low-dose
thiazide diuretics are usually very effective as add-on drugs.
Hypertension cannot be called “resistant” if a diuretic was not
included in the medications.257 In a recent analysis from the
ACCOMPLISH trial, thiazide-based treatment provided less
cardiovascular protection in normal weight than in obese pa-
tients, but amlodipine-based therapy was equally effective
across BMI subgroups and thus offers superior cardiovascular
protection in non-obese hypertension.258 Since averaged BMI
in Asians are lower than in Caucasians, thiazide diuretics
might be less effective in Asians as well. But double-blind
RCT to compare diuretics versus CCB in terms of cardio-
vascular outcomes has not been performed in Asia.
A major concern regarding the use of thiazide diuretics is
the plethora of metabolic side effects.259 Thiazides reduced
potassium, increased uric acid, and increased total cholesterol
and triglycerides.260 Hypokalemia was not uncommon in pa-
tients receiving thiazide diuretics. In the ALLHAT trial, the
relative risks of hypokalemia were 10.61 compared with the
lisinopril group and 4.50 compared with the amlodipine group.
The prevalence of hypokalemia (<3.5 mmol/l) was reported as
varying between approximately 7.2% and 8.5% at doses of
12.5-25 mg of chlorthalidone,261, 262 and up to 56% with
50 mg hydrochlorothiazide.263 Thiazide-induced hypokalemia
was more than twice as high in men as in women, and was
doses and age-related.264 The combination of triamterene
would not attenuate this side effect.264
The annual incidence of thiazide-induced hyponatremia
(130 mmol/L) is about 14%.265 Thiazide exposure was
associated with an almost 5 times higher risk of hyponatremia
(135 mmol/L) than no exposure.266 The risk did not differ
between male and female. Interestingly, the risk of hypona-
tremia due to thiazide exposure decreased with older age, and
higher BMI.266 The highest risk of hyponatremia with thiazide
exposure was seen within the highest eGFR quartile.266 Low-
dose thiazide is preferred in the treatment of hypertension to
avoid these electrolyte abnormalities.
In a recent meta-analysis, thiazide diuretic users had the
highest potential to develop new-onset diabetes.267 The long-
term impact of diuretic-induced diabetes on future cardio-
vascular events is controversial. In a post-hoc analysis ofALLHAT, patients with impaired fasting glucose actually have
significantly less CHD events in chlorthalidone group
compared with the amlodipine group in the 4 to 8-year follow-
up period of ALLHAT, in spite of an increase in diabetes
rate.268 The argument is that 4 to 8-year follow-up may be too
short to observe the negative impact of new-onset diabetes. In
a long-term cohort study of treated hypertension patients for a
follow-up of up to 16 years, the occurrence of new diabetes
portends a risk for subsequent cardiovascular disease that is
not dissimilar from that of previously known diabetes.269 In a
28-year follow-up of treated hypertension patients, new-onset
diabetes carries a significantly higher cardiovascular risk.270
The mean observation time from onset of diabetes to the
first stroke was 9.1 years, and it was 9.3 years to the first
myocardial infarction.270 Another important concern about
diuretics is the adverse events. In a meta-analysis of 354 trials,
the dose-dependence increase in the adverse effect of diuretic
is the most severe compared to other drugs.245 A dose more
than 25 mg/d of hydrochlorothiazide is considered to be a high
dose and is associated with a significant increase in side ef-
fects including metabolic derangement. According to recent
data from Canada, the long-term persistence rate was lowest
for users of diuretics, compared with users of other anti-
hypertensive drugs.271
Are all thiazide diuretics equally effective in lowering BP?
In a study comparing hydrochlorothiazide 50 mg/d with
chlorthalidone 25 mg/d, the latter provided a greater decrease
in ambulatory SBP, with the greatest difference occurring at
nighttime.272 From a retrospective observational cohort study
from the Multiple Risk Factor Intervention Trial (MRFIT) data
set, chlorthalidone displayed significantly lower SBP, lower
total cholesterol, lower LDL-C, lower potassium, and higher
uric acid over time compared with hydrochlorothiazide.273
The data for head-to-head comparison of indapamide versus
other thiazide diuretics could not be found.
For effects on cardiovascular outcomes, there is no RCT
for head-to-head comparison of different thiazides. RCTs
testing of thiazides versus comparators had neutral or wors-
ening effects, as shown in the ASCOT (benzofluthiazide)and
the ACCOMPLISH (hydrochlorothiazide) trial.243, 244 Inda-
pamide has outperformed placebo in some RCTs, such as the
PROGRESS trial,174 the ADVANCE trial,274 and the HYVET
trial.200 Chlorthalidone was quite successful in RCTs, such as
the SHEP trial and the ALLHAT trial.123, 256 Based on data
from meta-analysis of MRFIT, chlorthalidone users had
significantly fewer cardiovascular events compared with hy-
drochlorothiazide users (p ¼ 0.0016).273 In another meta-
analysis, chlorthalidone outperformed hydrochlorothiazide
in reducing cardiovascular events, after correction of differ-
ence in BP.275 These data suggested that chlorthalidone may
be the preferred thiazide-type diuretic for hypertension in
patients at high risk of cardiovascular events.273 Until a head-
to-head RCT is available, it is too early to reach a final
conclusion.
7.3.1.2. Mineralocorticoid receptor antagonists. Aldosterone
and its receptor have been shown to play important roles in the
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diovascular outcomes.276 Many reports have demonstrated that
circulating aldosterone levels are positively associated with
both incident277 and resistant hypertension278 (see definition
below), as well as obstructive sleep apnea- and obesity-related
hypertension.279, 280 In addition, the prevalence of primary
aldosteronism in hypertensive patients was reported to in-
crease along with hypertension stages.281 Hypertensive pa-
tients in the real world practice are less commonly to be
treated with aldosterone antagonists, given that almost 15-20%
of stage II-III patients have aldosterone hypersecretion.281
Importantly, patients with higher aldosterone levels but with
similar levels of BP still had significantly higher rates of
myocardial infarction, stroke and atrial fibrillation.282
According to currently available evidence, aldosterone an-
tagonists are beneficial for hypertensive patients with one of
the following two conditions: 1) primary aldosteronism; 2)
resistant hypertension. Solid evidence has also shown that
aldosterone antagonists significantly reduce mortality in pa-
tients with severe systolic heart failure,283 or with prior
myocardial infarction,284 and even in patients with mild sys-
tolic heart failure.285 However, the enrolled patients in these
clinical trials were basically normotensive and there has been
no data revealing outcomes for hypertensive subgroup, making
it difficult to see whether aldosterone antagonists would add
additional benefits to hypertensive patients with systolic heart
failure when standard heart failure treatment has been pro-
vided. On the other hand, the effects of spironolactone on
heart failure with preserved ejection fraction patients, who are
characterized by a high prevalence rate (>90%) of hyperten-
sion, have recently been evaluated in a small-scale study (total
422 patients).286 There was significant improvement in left
ventricular diastolic function, left ventricular remodeling, and
N-terminal-proBNP levels, but no benefit on clinical symp-
toms and outcomes.286 In a similar but larger scale randomized
clinical trial in patients with heart failure and a preserved
ejection fraction (TOPCAT), treatment with spironolactone
did not significantly reduce the incidence of the primary
composite outcome including death from cardiovascular
causes.287
Treatment-resistant hypertension (TRH) is defined in a recent
review as high BP (140/90 mmHg), resistant to a treatment
regimen that includes proper lifestyle modification plus a
diuretic and two other antihypertensive agents of different
classes at their optimal doses.288 Among patients with resistant
hypertension, the prevalence of primary aldosteronism is around
17 to 23%.278, 281 Other possible reasons accounting for high
aldosterone levels in patients with resistant hypertension are a
rebound after volume reduction by diuretics289 or an escape from
early reduction associated with RAS blockade.290 Over-
whelming evidence has confirmed that aldosterone antagonists,
even at low doses, were effective in resistant hyper-
tension.291e296 Adding spironolactone 25 mg/day is more
effective in BP reduction than adding ramipril 5 mg/day to a
background irbesartan treatment in resistant hypertension.296 In
patients with resistant hypertension, who had received the
combination of irbesartan, hydrochlorothiazide, and amlodipine,adding 25 mg spironolactone was more effective than adding
5 mg ramipril in reducing daytime ABPM (19/11 vs 8/
7 mmHg, p ¼ 0.0003) and left ventricular mass index.297 In the
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) sub-
study, spironolactone was an effective add-on drug after treat-
ment with two or more antihypertensive combination.291
ASPIRANT (Addition of Spironolactone in Patients with
Resistant Arterial Hypertension Trial) is currently the only
double-blind RCT to evaluate the effect of aldosterone antago-
nist in resistant hypertension.295 With a high percentage of
background RAS blockade coverage (76.5% and 46.5% with
ACE inhibitors and ARB, respectively), the addition of spi-
ronolactone decreased SBP by 9.8 mmHg on ABPM and also
significantly improved microalbuminuria.295 A similar BP
reduction in ABPM was observed in another RCT involving
patients with resistant hypertension and diabetes mellitus when
spironolactone was added to a triple-drug regimen containing
either ACE inhibitors or ARBs.298 Eplerenone, a more selective
mineralocorticoid receptor antagonist without the anti-
androgenic effects, was associated with a 10-mmHg reduction
in SBP in ABPM, when used as a fourth-line agent at the dose of
50 mg twice daily.299 The antihypertensive associations of both
spironolactone and eplerenone were observed even in the pres-
ence of normal serum aldosterone levels.295, 299
Although aldosterone antagonists are effective add-on
drugs for resistant hypertension, caution has to be taken
when adding them to background RAS inhibitors. The
occurrence of hyperkalemia and the possibility of rapid
reduction of eGFR should be carefully monitored. The addi-
tion of aldosterone antagonists is generally contraindicated if
serum potassium levels >5.0 meq/l, and should be used with
caution if eGFR is less than 30 ml/min/1.73 m2.288
7.3.1.3. Loop diuretics. Loop diuretics are less effective than
thiazide diuretics in lowering BP, so that their major use is in
edematous patients with congestive heart failure, and in pa-
tients with more severe CKD (eGFR < 30 ml/min/1.73 m2).300
Loop diuretics should not be used as first-line therapy in hy-
pertension since they have generated no outcome data. They
can be combined with thiazide-type diuretics.300
7.3.1.4. Other potassium-sparing diuretics. Other potassium-
sparing diuretics, such as amiloride and triamterene, block
the epithelial sodium channel. They are widely prescribed for
hypertension as a second line drug in patients taking other
diuretics (e.g. thiazide diuretics). However, there has been no
trial evaluating the BP lowering efficacy of these drugs as
monotherapy in patients with primary hypertension. Even in
trials evaluating the efficacy of low doses of amiloride and
triamterene as a second drug, BP was not reduced.300 There-
fore, these agents should not be routinely used.
7.3.2. Beta-blockers
Whether beta-blockers should be placed as one of the first-
line drugs for hypertension is probably the most controversial
among major hypertension guidelines.10, 11 (http://pathways.
nice.org.uk/pathways/hypertension) The ESH/ESC 2013
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beta-blocker as a first-line drug.10 However, the 2014 JNC
report rejected it as a first-line drug.11 The 2014 NICE hy-
pertension guides put beta-blockers as step-4 drugs. (http://
pathways.nice.org.uk/pathways/hypertension) According to
the largest meta-analysis of 147 trials consisting of 958,000
people,165 all major classes of anti-hypertensive drugs,
including beta-blockers, reduced CHD and stroke when
compared to placebo. Beta-blockers had a special benefit in
preventing recurrent CHD events in people with a history of
CHD: a risk reduction of 29% compared with 15% in trials of
other drugs, though the extra effect was limited to a few years
after myocardial infarction.165 But in patients without CHD,
beta-blockers increased stroke by 18%, while CCB decreased
stroke by 9% (all P < 0.05). It has been demonstrated In the
meta-analysis of BPLTTC that beta-blockers had a similar
effect in reducing CV events compared to other drug classes,
and no sign of increasing stroke rate was found.239 It has
recently been shown that there might be some differences in
the effects of atenolol versus non-atenolol beta-blockers.301 In
the meta-analysis including 145,811 patients, it was shown
that among the elderly (60 years) atenolol was associated
with an increased risk of stroke (relative risk 1.17, p < 0.05)
compared with other anti-hypertensive drugs.301 The risk of
stroke for non-atenolol beta-blockers, when compared with
other drugs, did not reach statistical difference. In the young
(age <60 years), atenolol was associated with reduced risk of
stroke compared with other drugs (relative risk 0.78, p < 0.05),
whereas non-atenolol beta-blockers were associated with a
lower risk of composite cardiac events (relative risk 0.86,
p < 0.05) compared with placebo, with no significant differ-
ences in events compared with other drugs.301 It seems that all
the beta-blockers, including atenolol and non-atenolol drugs,
performed equally well in the young (<60 years) compared to
other drugs.301 Only in the elderly (60 years), atenolol was
inferior to other drugs in reducing stroke.301 In this guideline,
we suggest that beta-blockers, except atenolol, can be used as
the first-line therapy, especially in patients with CHD, history
of myocardial infarction, and in patients with higher heart rate
(80 beats/min).
Bronchial asthma is an absolute contraindication for the use
of both beta-1 selective or non-selective beta-blockers, but
chronic obstructive pulmonary disease (COPD) is not a
contraindication. In an observational cohort study, treatment
with beta-blockers reduced the risk of exacerbation and
improved survival in patients with COPD.302 In a retrospective
cohort study, beta-1 selective, but not non-selective, beta-
blockers were suggested to be safe in patients hospitalized
with acute exacerbation of COPD with underlying CHD, heart
failure, or hypertension.303 But in a retrospective analysis of
the OPTIMIZE-HF registry,304 both beta-1 selective and non-
selective beta-blockers were associated with lower death rate
in patients with and without COPD.304 There was no evidence
that beta-blocker selectivity was associated with a difference
in outcomes between patients with and without COPD.305
The major side effects with beta-blockers are reduced
sexual function, fatigue, reduced exercise capacity, and bodyweight increase. One important side effect is new-onset dia-
betes,267, 306 especially in combination with diuretics.
7.3.2.1. Atenolol. In the LIFE trial and the ASCOT trial,242,
243 atenolol was the main component of one of the treatment
arms. Compared with ARB, atenolol group had higher car-
diovascular events, especially stroke.242 Atenolol, in combi-
nation of thiazide diuretics, has an increased total mortality
and cardiovascular events, compared with the combination of
CCB and ACE inhibitors in the ASCOT trial.243 A possible
reason for the increase in cardiovascular events, especially
stroke, is that atenolol was less effective in decreasing central
aortic pressure and pulse pressure.83, 307 Another possible
reason is that atenolol has a short half-life of about 6-9
hours,308 but most RCTs for atenolol took a QD dosing
regimen. In a meta-analysis comparing beta-blockers (mainly
atenolol) with other anti-hypertensive drugs, beta-blockers
increased the risk of cardiovascular events and death for hy-
pertensive patients.309 It is suggested that atenolol should not
be used as a first-line beta-blocker in the treatment of hyper-
tension, especially for patients aged 60 years.
7.3.2.2. Non-atenolol beta-blockers. Other beta-blockers,
such as metoprolol and bisoprolol, have not been extensively
tested in RCTs. The effect of bisoprolol versus atenolol on
central aortic pressure is more controversial.310, 311 Newer
vasodilating beta-blockers, such as carvedilol or nebivolol,
reduced central pulse pressure and aortic stiffness better than
atenolol or metoprolol.312-314 Both nebivolol and carvedilol
have a favorable effect on blood glucose compared to meto-
prolol,315, 316 and have been favorably tested in RCTs for heart
failure.317-319 There has been no RCT to test their long-term
cardiovascular effects in patients with hypertension.
7.3.3. Calcium channel blockers (CCBs)
CCBs have potent BP-lowering effects, and have been the
most widely used anti-hypertensive drugs, especially in Asia.
Several recent large clinical trials have confirmed their effi-
cacy not only in lowering BP but also in reducing cardiovas-
cular morbidity and mortality in hypertensive patients with a
normal or high cardiovascular risk profile. CCBs can be
broadly classified into 2 groups: dihydropyridine (DHP) and
non-dihydropyridine (non-DHP) groups. Most of the recent
RCTs tested DHP CCBs, whereas RCTs for non-DHP CCBs
occur much less frequent.
7.3.3.1. Dihydropyridine calcium channel blockers (DHP
CCBs). Short-acting DHP CCBs cause reflex tachycardia and
are generally not recommended as first-line anti-hypertensive
drugs. The effect of nitrendipine versus placebo in reducing
stroke in isolated systolic hypertension has been confirmed in
the Syst-Eur and Syst-China trials.124, 125 Other DHP CCBs
have also been studied in RCTs, including the INSIGHT
trial,320 the HOT trial,136 and the FEVER trial.133 In the
ALLHAT trial,256 the CAMELOT trial,160 the VALUE trial,253
or the ASCOT trial,243 an amlodipine-based therapy was at
least as effective, when not slightly superior, in lowering BP
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lowering strategies based on the use of diuretics, beta-blockers
and blockers of the renin-angiotensin system.160, 243, 253, 256 In
the ACCOMPLISH trial, the combination of ACE inhibitor
and amlodipine was superior to the combination of ACE in-
hibitor and a thiazide diuretic in reducing composite CV
endpoints.244 According a meta-analysis of 147 trials, DHP
CCB is the most effective drug class to decrease stroke.165 The
efficacy of CCBs may be due to their potent BP-lowering
effect, and the ability to decrease BP variability.104 However,
DHP CCBs might be less effective in reducing heart failure, as
reported in the ALLHAT trial,256 the VALUE trial,253 and the
ACCOMPLISH trial.244 In the meta-analysis of 147 trials,
CCB was less effective in reducing heart failure compared to
other anti-hypertensive drugs.165
In Asians more specifically, the effects of DHB CCBs have
been tested in the Syst-China trial and the FEVER trial.125, 133
In the felodipine group in the FEVER trial, the primary
endpoint (fatal and non-fatal stroke) was reduced by 27%
(p ¼ 0.001).133 Among secondary endpoints, all cardiovas-
cular events were reduced by 27% (p < 0.001), and all-cause
death by 31% (p ¼ 0.006) in the felodipine group.133 A meta-
analysis of 12 trials reported that DHP CCB was more
effective than other anti-hypertensive drugs in reducing both
day-time and night-time SBP in east Asians.321
The main side effect of DHP CCBs is peripheral edema,
which is most prominent at high doses. This side effect can be
attenuated by combining these agents with ACE inhibitors,
ARBs, or direct renin inhibitors (DRI).322 More importantly,
there is no contraindication for the use of DHP CCBs
(Table 13).
7.3.3.2. Non-dihydropyridine calcium channel blockers. Non-
DHP CCBs, include verapamil and diltiazem, are less potent
than DHP groups, but generally non-inferior to comparators in
several RCT.141, 323, 324 Diltiazem could decrease albuminuria
in a small scale RCT.325 Non-DHP CCB are more negatively
chronotropic and inotropic than the DHP groups, and have
more contraindications as shown in Table 13. Both verapamil
and diltiazem are metabolized by CYP3A4, and have more
drug-drug interaction than DHP group.326 In general, non-
DHP CCBs should not be used as first-line drugs in the
treatment of hypertension.
7.3.4. Angiotensin converting enzyme (ACE) inhibitors
ACE inhibitors have been extensively studies in many RCTs
for the treatment of hypertension.174, 256 Even in high risk
patients with pre-hypertension (120-139/80-89 mmHg), several
RCTs have confirmed their efficacy and safety compared to
placebo or other anti-hypertensive drugs.156, 157, 327 ACE
inhibitors are preferentially indicated in patients with heart
failure,328-332 diabetes,274, 333-335 and CKD.182, 183 336, 337
The major side effects of ACE inhibitors include cough and
angioedema. The incidence of ACE inhibitor-induced cough is
reported to be 5-35%.338 It is generally believed that cough
due to ACE inhibitors are more common in Asians.339, 340
Although ACE inhibitor-induced cough seems to be a classeffect, some reports claimed that certain ACE inhibitors might
have less cough than others.341, 342 The major dangerous side
effect of ACEI inhibitors is angioedema.343 Fortunately, its
incidence is <1%,344 and is especially rare in Chinese.345
7.3.5. Angiotensin receptor blockers (ARBs)
ARBs have been proven by multiple RCTs to be effective
in reducing BP and cardiovascular events.188-190, 242, 327, 337,
346-348 Because they are well-tolerated and have effects and
benefits similar to ACE inhibitors,327 they are now generally
preferred over ACE inhibitors. But ARBs should not be
combined with ACE inhibitors, because both its side effects
and acute renal impairment were higher than in monotherapy
with ACE inhibitor or ARB.327
The tolerability of ARBs is the highest, and the discon-
tinuation rate is the lowest among all 5 classes of anti-
hypertensive drugs.242, 327 Cough and angioedema were very
rarely reported in patients receiving ARBs.327
7.3.6. Direct renin inhibitor (DRI)
The only available DRI, aliskiren, has been shown to be
effective in lowering BP,349 and has favorable effects on TOD,
such as proteinuria or left ventricular hypertrophy,350, 351 or on
biomarkers for heart failure.352 In a large RCT,353 aliskiren
was added on top of pre-existing ACE inhibitor or ARB in
patients with high risk diabetes. The trial was prematurely
terminated due to a non-significant increase in primary end-
points, and an increase in adverse events, such as hyper-
kalemia and hypotension.353 The RCT testing the effect of
aliskiren, on top of ACE inhibitors or ARBS, in heart failure
had a neutral effect, but had increased adverse events, such as
hyperkalemia, hypotension and renal impairment.354 Never-
theless, aliskiren can be safely combined with hydrochloro-
thiazide or amlodipine in the elderly (age 65 years) with
stage 1 hypertension, as shown in the APOLLO trial.355 The
contraindications for aliskiren are similar to ACE inhibitors or
ARBs (Table 13).
7.3.7. Other anti-hypertensive agents
Alpha-blockers are less widely used as a first-line drug for
hypertension, especially after the ALLHAT trial showing
increased heart failure by the use of doxazosin compared with
the use of chlorthalidone.356 However, there has been some
disagreement about the design of the ALLHAT trial. Dox-
azosin can be used in the treatment of resistant hypertension
when combined with other drugs.243 Alpha-blockers are
effective in the treatment of benign prostate hypertrophy, and
are a valuable part of hypertension treatment regimens in
elderly men.
Centrally acting drugs, such as clonidine and alpha-
methydopa, have bothersome side effects and have not been
proven in RCTs. They are not recommended as first-line
therapy. The use of alpha-methyldopa in pregnancy was dis-
cussed in Section 8.2.
Direct vasodilators, such as hydralazine and minoxidil,
cause fluid retention and tachycardia. No RCTs for the treat-
ment of hypertension have been done for hydralazine, nor for
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tachycardia, hemolytic anemia, vasculitis, glomerulonephritis,
and a lupus-like syndrome.357 However, hydralazine in com-
bination with isosorbide dinitrate, is effective in African-
Americans who have symptomatic heart failure.359 Because
of the severity of adverse effects with minoxidil, its usage is
limited to persons with severe hypertension unresponsive to
other treatment.358 Vasodilators should not be used as first-line
anti-hypertensive drugs.
Among all the drugs in the investigational stages, LCZ696
merits additional mention here. LCZ696 is a dual-acting
angiotensin receptor-neprilysin inhibitor (ARNI).360 In a
proof-of-concept trial, LCZ696 was compared with valsar-
tan.361 LCZ696 provides complementary and fully additive
reduction of BP, and no cases of angioedema were reported.361
Though LCZ 696 has not been approved for the treatment of
hypertension, it has been successfully tested in patients with
systolic heart failure. In the PARADIGM trial, 8442 patients
with class II-IV heart failure and an ejection fraction <40%
were enrolled.362 LCZ696 was demonstrated to be superior to
enalapril in reducing the risks of death and hospitalization for
heart failure (20%, p < 0.0001).3627.4. Combination therapyPatients with hypertension may have different pathophysi-
ological derangement.363 Therefore, combining drugs with
different anti-hypertensive mechanisms may be more effective
than titrating doses of a single agent. Indeed, multiple classes
of drugs might be needed in clinical practice to control BP to
targets. In the ALLHAT trial, an average of 2 drugs were
required for SBP control in two thirds of participants, but only
67% of patients reached SBP targets by the end of the trial.364
In the ASCOT trial, only 27% patients were on monotherapy
and 73% on 2 or more drug after 3.5 years of follow-up.243
According to the “Rule of 10” (Fig. 3) and “Rule of 5”
(Fig. 4), a standard dose of every drug can decrease SBP by
approximate 10 mmHg, and DBP by 5 mmHg.9, 245 Preferably,
when 2 drugs with different mechanisms are taken together,
the decrease in BP is the sum of the decrease of the individual
agents (approximately 20 mmHg in SBP and 10 mmHg in
DBP).9, 245, 246 Therefore, in order to treat to a target of 140/
90 mmHg in patients with a pre-treatment BP of 160/
90 mmHg or above, two drugs are usually needed.
In order to control BP sooner to targets, early combination
is suggested by this guideline. In a population-based, nested
case-control study of 209,650 patients, those who were treated
with initial combination therapy and were maintained on
combination therapy along the entire period, had a 26% lower
CV risk compared with patients who maintained monotherapy
throughout the treatment course.365
Based on data from a meta-analysis of 354 randomized,
double-blind, placebo-control trials comprising 40,000 drug-
treated patients and 16,000 placebo-treated patients,245 the
BP lowering effects of different classes of drugs were addi-
tive.245 Side effects attributable to thiazides, beta blockers, and
CCBs were strongly dose-related; side effects caused by ACEinhibitors (mainly cough) were not dose-related.245 ARBs
caused no excess of side effects. The prevalence of side effects
with two drugs in combination was less than additive. Adverse
metabolic effects were negligible at half of the standard
doses.245 The conclusion is that a combination of low doses of
drugs increases efficacy and reduces adverse effects.245 A
similar finding was reported recently that initiating treatment
with a combination of two drugs is associated with a reduced
risk of treatment discontinuation.366
7.4.1. Choice of combination
Three large-scale RCTs have tested the superiority of one
combination versus the other.242-244 In the LIFE trial, the
combination of losartan (ARB) plus hydrochlorothiazide
(diuretic) was compared with the combination of atenolol
(beta-blocker) plus hydrochlorothiazide (diuretic), showing
that ARBþdiuretic combination was better than beta-block-
erþdiuretic combination in reducing CV endpoints, mainly
stroke.242 The difference of achieved SBP was only
1.3 mmHg, lower in the ARBþdiuretic group. In the ASCOT
trial, the combination of amlodipineþperindopril (CCBþACE
inhibitor) was better than the combination of ateno-
lolþbenzofluthiazide (beta-blockerþdiuretic) in reducing total
mortality and other CV endpoints with a SBP difference of
2.7 mmHg, lower in the CCBþACE inhibitor group.243 Be-
sides, the risk of new-onset diabetes from the combination of
beta-blockerþdiuretic was higher than other combinations.367
Therefore, the combination of beta-blockerþdiuretic is infe-
rior to the combination of ARBþdiuretic or CCBþACE in-
hibitor combinations.
The strongest evidence supporting the combination of ACE
inhibitorþCCB came from the ACCOMPLISH trial.244 In this
double-blinded RCT, the single-pill combination (SPC) of
benazeprilþamlodipine (ACE inhibitorþCCB) was compared
with the SPC of benazeprilþhydrochlorothiazide (ACE
inhibitorþdiuretic). This trial was prematurely terminated due
to overwhelming benefits in reducing CV endpoints favoring
the combination of ACE inhibitorþCCB, though the SBP was
only 0.9 mmHg lower in the ACE inhibitorþCCB group.244
The benefits of ACE inhibitorþCCB combination could not
be explained by the difference in ABPM, because the mean
SBP was 125.3 mmHg for ACE inhibitorþCCB group, and
123.7 mmHg for ACE inhibitorþdiuretic group.368 The renal
outcomes also favored the ACE inhibitorþCCB combina-
tion.369 In a subgroup analysis in diabetic patients, the ACE
inhibitorþCCB combination were similarly superior to the
ACE inhibitorþdiuretic combination.368 Almost all CV end-
points and renal endpoints, except heart failure admission,
were lower in the ACE inhibitorþCCB group.368 In a post-hoc
analysis in high-risk patients with stage 2 hypertension in the
ACCOMPLISH trial, the combination of benaze-
prilþamlodipine has also been shown to be better than the
combination of benazeprilþdiuretic therapy.370 One finding in
the ACCOMPLISH trial that might be related to the Asian
patients is that the combination of ACE inhibitorþdiuretic
gave less cardiovascular protection in normal weight than in
obese patients, but ACE inhibitorþamlodipine combination
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superior cardiovascular protection in non-obese hypertension,
such as in Asian patients.258 But we do need an RCT involving
an Asian population to prove this.
When compared to the ALLHAT trial in which diuretic-
based therapy was not inferior to ACE inhibitor-based or
CCB-based therapy,256 it appears that CCB is better than
diuretic as a component in combination therapy. However,
chlorthalidone was used in the ALLHAT trial whereas hy-
drochlorothiazide was used in the ACCOMPLISH trial.244, 256
Recommended 2-drug combinations include:
✓ ARBþCCB (AþC)
✓ ACE inhibitorþCCB (AþC)
✓ ARBþthiazide diuretic (AþD)
✓ ACE inhibitorþthiazide diuretic (AþD)
✓ CCBþbeta-blocker (BþC)
There have been no RCTs to test the efficacy of any 3-drug
combination in reducing CV endpoints. Based on the patho-
physiological mechanism of hypertension, we recommended
ACE inhibitor (or ARB)þCCBþThiazide diuretic (AþCþD)
combination. A post-hoc analysis of the ADVANCE trial
shows that the combination of perindopril and indapamide
with CCBs (AþCþD) provided further protection in reducing
mortality in patients with type 2 diabetes.371 In patients with
heart failure or CHD, or with a high resting heart rate, beta-
blockers may precede thiazide diuretics. Alpha-blocker has
been used as the third drug in the ASCOT trial,243 but its
priority is usually lower than diuretics.
Some unfavorable combinations were listed below. Com-
bination of a beta-blocker and a thiazide diuretic should be
used with great caution because of higher diabetogenic po-
tential.267 The combination of 2 drugs of renin-angiotensin
system inhibitors is generally prohibited. The risk of hyper-
kalemia and renal impairment have been shown both in RCTs
and in a population-based cohort study.327, 353, 372, 373
Unfavorable or prohibited 2-drug combinations include:
Beta-blocker þ diuretic (except in heart failure)
ACE inhibitor þ ARB
(ACE inhibitor or ARB) þ DRI7.4.2. Single-pill combination
Combining anti-hypertensive drugs of different classes in a
single tablet (single pill combination, SPC), previously called
fixed-dose combination, has become more common in daily
practice. In general, SPCs of antihypertensive agents reduce pill
burden, and are associated with a significant improvement in
compliance, compared with free-drug combinations.374, 375 Use
of SPC could help patients to continue treatment and result in
lower BP than in free combination.376 Interesting findings came
from a recent report from the NHIRD in Taiwan that SPC is not
effective in patients adequately adhering to their free-combined
antihypertensive regimens.377 But it is generally accepted that
initial therapy with SPCs provided better hypertension controlin the first year than free combinations or monotherapy.378 In
the STITCH trial (Simplified Treatment Intervention to Control
Hypertension) done in Canada, initial use of SBP was associ-
ated with a significant decrease of 5.4 mmHg in SBP compared
to the free combination group.379 SPC also increased the chance
of reaching the target by 20%.379 The use of SPC was also
associated with a trend of less adverse events than free com-
bination.374 SPC of anti-hypertensive drugs, statin, and aspirin
was tested in the UMPIRE trial.380 Use of SPC resulted in
significantly improved medication adherence.380
The most successful experience came from the recent
report from the Kaiser Permanente Northern California
(KPNC) hypertension program. From 2001 to 2009, the con-
trol rate of hypertension increased from 43.6% to 80.4%. One
of the key factors was the widespread use of SPC.381 There-
fore, in this guideline, the use of SPC is encouraged. In pa-
tients with BP 160/100 mmHg, or in special patient group
whose BP is >150/90 mmHg, SPC can be used as the first-line
therapy (Fig. 2).7.5. Treatment algorithmA treatment algorithm was shown in Fig. 2. The initial
treatment should always include LSM (Please see Section 7.1).
When drug therapy is considered, a strategy called “PRO-
CEED” can be considered (Section 7.2). As mentioned before,
special patient groups include patients with diabetes, CHD,
and CKD with proteinuria. The suggestions about drug ther-
apy in this algorithm are not applicable to very elderly patients
(age 80 years).
For patients who do not belong to special patient groups,
LSM is the initial treatment for the first 3 months in patients
with a stage 1 hypertension (BP ¼ 140e159/90e99 mmHg).
If BP is still >140/90 mmHg after 3 months, pharmacological
therapy with 1 drug should be initiated. For patients with stage
2 HT (BP ¼ 160e179/100e109 mmHg) or stage 3 HT
(BP180/110 mmHg), drug therapy should be combined with
LSM as the initial step. Two-drug combination, or SPC of 2
drugs, can be considered in patients with stage 2 HT. We
recommend a 3-drug combination for patients with stage 3
hypertension, except in fragile patients, or patients with
postural hypotension, or patients 80 years of age. SPC of 3
drugs may be considered in patients with stage 3 HT, if an
initial combination of 2 drugs has failed.
For patients who belong to special patient groups, LSM is
still the initial treatment for the first 3 months in patients with
baseline BP of 130e149/80e89 mmHg. If BP is still >130/
80 mmHg after 3 months, pharmacological therapy with 1
drug should be initiated. For patients with baseline BP 150/
90 mmHg, drug therapy should be combined with LSM as the
initial step. A two-drug combination, or SPC of 2 drugs, can
be considered in patients with BP of 150e169/90e99 mmHg.
We recommend a 3-drug combination for patients with BP
170/100 mmHg, except in fragile patients, or patients with
postural hypotension, or patients 80 years of age. SPC of 3
drugs may be considered in patients with BP 170/
100 mmHg, if an initial combination of 2 drugs has failed.
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vative strategy is taken. Because BP targets are <150/
90 mmHg, we suggest that drug therapy be initiated when
baseline BP is150/90mmHg. A two-drug combination can be
used when baseline BP is 170/100 mmHg. A three-drug
combination is not suggested as the initial therapy, unless a 2-
drug combination is not effective. Titration of medications
should be more careful in elderly patients who have experi-
enced a previous fall.382 On the other hand, the control of BP in
the very elderly patients (80 years) should not be delayed. In
the one-year open-labeled extension trial of the HYVET study,
participants on active BP lowering treatment continued taking
active drug; those on placebo were given active BP lowering
treatment.383 By 6 months, the difference in BP between the
two groups was only 1.2/0.7 mmHg. However, total mortality
and cardiovascular mortality were still lower in the previously
treated group (HR 0.48, p ¼ 0.02; HR 0.19, p ¼ 0.03; respec-
tively).383 This finding suggested that early and long-term
treatment of hypertension in very elderly patients is beneficial.7.6. Adjustment algorithmThe effect of antihypertensive drugs reached to 50% and
80% of their maximal effects in 1 week and 2 weeks,
respectively.384 Therefore, a period of 2 to 4 weeks of treat-
ment is allowed before adjustment of management. If BPs are
not at goals after 4 weeks of treatment, adjustment of man-
agement is suggested. An Adjustment algorithm called “AT
GOALs” is shown in Fig. 5: Adherence, Timing of adminis-
tration, Greater doses, Other classes of drugs, Alternative
combination or SPC, and LSM (þLaboratory tests).
The first thing is to re-confirm patient adherence, because
non-adherence is very common in daily practice.385 Timing of
drug administration can be adjusted according to the diurnal
BP profile of individual patients, provided by ABPM or
HBPM. If early morning hypertension is observed, switching
of medication from morning dosing to bedtime dosing may be
useful. Increasing or maximizing doses should be consideredFig. 5. Adjustment algorithm. BP ¼ blood pressure.thereafter. The next step is to add or switch to other classes of
drugs, or to use different combination of drugs, including SPC.
LSM needs to be intensified, too. Medications should be
modified by findings from laboratory tests. For instance, if
there is a deterioration of renal function in patients using AþD
combination, AþC should replace AþD. In patients suffered
from hypokalemia by the use of thiazide diuretics, mineralo-
corticoid receptor antagonist is a reasonable alternative.7.7. Non-pharmacological therapy
7.7.1. Renal nerve denervation
The sympathetic nervous system seems to play an impor-
tant role in resistant hypertension.386 More recently, dener-
vation of the renal arteries by radiofrequency energy has
emerged as a potentially effective procedure to treat resistant
hypertension.387, 388 Initial un-blinded trials have shown sig-
nificant reductions in office BP.389, 390 There is an over-
whelming enthusiasm for performing this procedure in
patients with resistant hypertension.391, 392
In the SYMPLICITY HTN-3 trial, a single-blind RCTwith a
sham-controlled group, a total of 535 patients were random-
ized.393 The baseline office BPs were 179.7/96.5 mmHg in the
denervation group, and 180.2/98.9 mmHg in the sham group,
under a mean of 5 anti-hypertensive drugs of different classes.
The primary efficacy endpoints (change in office SBP at 6
months) were 14.13 mmHg in the denervation group as
compared with11.74 mmHg in the sham-group (p¼ 0.26).393
The secondary efficacy endpoints (change in mean SBP in
ABPM) were6.75 mmHg vs4.79 mmHg (p¼ 0.98).394 No
significant differences in the safety endpoints were observed.
The SYMPLICITY HTN-3 trial brings the renal-denervation
train to a grinding halt.395 It has been suggested in a recent
publication that adjustment of drug treatment had superior BP
lowering effects compared with renal denervation in patients
with true treatment-resistant hypertension.396
7.7.2. Other non-pharmacological therapy
Devices that stimulate the carotid baroreflex have been
developed to treat patients with hypertension.360 Activation of
central baroreflex pathways by continuous electrical stimula-
tion of the nerves of carotid sinus baroreceptors reduced
sympathetic outflow from the central nervous system and
reduced BP.397 Results from a double-blind, randomized,
placebo-controlled pivotal trial of 265 subjects with resistant
hypertension did not meet the endpoints for acute responders
or procedural safety.398 Thus, all the non-pharmacological
therapies, including deep brain stimulation, brainstem neuro-
vascular decompression, etc. are still in the investigation stage,
and have not yet reached clinical practice.360
8. Treatment strategies in special conditions8.1. Treatment resistant hypertensionTRH was defined by the American Heart Association as BP
above goals on 3 medications or controlled to goal on  4
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diuretic.399 The prevalence of TRH has been reported to range
from 5 to 30% of the overall hypertensive population.10, 399
However, the true percentage might be lower than what has
been previously shown.257, 400, 401 The prevalence of TRH was
12.7% in the REACH registry,402 but was only 1.9% from a
recent report from the combined Kaiser Northern California
and Kaiser Colorado databases.403 TRH is associated with a
high cardiovascular risks. In the sub-analyses of the REACH
registry,402 the INVEST trial,404 and the Kaiser database,403
patients with TRH had higher risk of composite cardiovascu-
lar events than patients with controlled hypertension (hazard
ratios 1.11, 1.27, and 1.47, respectively, all p < 0.05).402-404
Before making a diagnosis of TRH, care must be taken to
exclude the white-coat effect and non-adherence.288 The
prevalence of white-coat effect may be as high as 30% among
patients with elevated office BP despite treatment with at least
3 drugs.405 Non-adherence is another important cause of
pseudo-resistant hypertension.288 Medication non-adherence is
very common in daily practice,385 and might be as high as 8 to
40%, detected by use of questionnaires or pharmacy refill
data.406, 407 If therapeutic drug monitoring using serum sam-
ples was applied, the prevalence of non-adherence would be
50-60%.408 Other causes of TRH are shown in Table 14.
LSM should be intensified in patients with TRH. Sodium
restriction is the most important modification among all the
strategies in LSM. Intensive sodium lowering might decrease
BP by 23/9 mmHg in ABPM in patients with TRH.213 Phys-
ical inactivity is also very common in patients with TRH, and
could be identified in more than 40% of patients.409 A recent
RCT in patients with resistant hypertension, consisting of
walking on a treadmill 3 times weekly for 8-12 weeks, has
demonstrated a 6/3 mmHg reduction in ABPM compared with
sedentary control group.410
Drug therapy for TRH should begin with optimization of
diuretic use.406 While hydrochlorothiazide 12.5 mg/d to
25 mg/d is the most commonly prescribed antihypertensive
drug worldwide, and the most common component in the SPC,Table 14
Causes of treatment resistant hypertension.
Improper blood pressure measurement technique
Failure to modify lifestyle including
Heavy sodium intake
Weight gain
Heavy alcohol intake
Intake of drugs that raise blood pressure
Cocaine, sympathomimetics, glucocorticoids, non-steroidal
anti-inflammatory drugs, erythropoietin, cyclosporine, anti-VEGF, etc.
Obstructive sleep apnea
Unsuspected secondary hypertension
Irreversible or scarcely reverse organ damage
Volume overload due to:
Inadequate diuretic therapy
Progressive renal insufficiency
High sodium intake
Hyperaldosteronism
VEGF ¼ vascular endothelial growth factor.
(Modified from Chiang et al.9 with permission.)50 mg/d hydrochlorothiazide was more effective in reducing
ABPM than doses of 12.5 mg/d or 25 mg/d.411 Metabolic
effects of high dose thiazide are a concern. Chlorthalidone is at
least twice as potent as hydrochlorothiazide,412 and should be
considered as the initial therapy for patients with TRH.288 In
fact, chlorthalidone is the only diuretic recommended by the
2008 AHA position statement.399 However, chlorthalidone is
not available in Taiwan. NICE hypertension guideline rec-
ommended indapamide instead of hydrochlorothiazide for
TRH. (http://pathways.nice.org.uk/pathways/hypertension)
Given the prevalence of sub-clinical or clinical apparent
mineralocorticoid excess of up to 20% in patients with
TRH,278 the 2008 AHA position statement proposed the use of
aldosterone antagonists as part of a multi-drug regimen.399 In
the ASCOT trial, adding spironolactone as the fourth-line drug
decreased office BP by 21.9/9.5 mmHg in approximately 1400
patients.291 The ASPIRANT (Addition of Spironolactone in
Patients with Resistant Arterial Hypertension Trial) is the only
double-blind RCT to evaluate the effect of aldosterone
antagonist in resistant hypertension.295 With a high percentage
of RAS blockade coverage (76.5% and 46.5% with ACE in-
hibitors and ARB, respectively), the addition of spironolactone
was still able to decrease SBP further by 9.8 mmHg on ABPM
and also significantly improved microalbuminuria.295 Because
the potential risk of hyperkalemia with mineralocorticoid re-
ceptor antagonists, they may counteract the risk of hypokale-
mia by thiazide diuretics. Thus, spironolactone or eplerenone
can be initiated and combined with thiazide diuretics before
maximizing the doses of thiazide diuretics.
Alpha-blockers can be considered as the fourth-line drug,
but the priority of use of alpha-blocker should be after the use
of mineralocorticoid receptor antagonists. Beta-blockers can
be used as the fourth-line drug if the resting heart rate is high.
Non-pharmacological therapy, such as baroreceptor stimula-
tion or renal denervation, are to date, either unsuccessful or
unproven in the management of TRH.395, 3988.2. Hypertension in womenBoth SBP and DBP are generally lower in pre-menopausal
women (<50 years) than in men at the same age.6, 8 On the
other hand, SBP increases more rapidly with age in women
than in men.8 After the age of 60, women have higher BPs and
higher prevalence of hypertension than men.8 According to the
TwSHHH conducted in 2002, women with indigenous ancestry
had a 2-fold higher prevalence of hypertension compared to
women with mainland ancestry.413 The continuous relationship
between BP and cardiovascular events is similar between men
and women. In a meta-analysis of 31 RCTs including 103,268
men and 87,349 women, the efficacy of antihypertensive drugs
with regard to BP reduction and cardiovascular protection is
comparable for men and women.414 However, there is still no
large-scale (>1000 patients) RCT specifically enrolling female
hypertensive patients to assess the efficacy of antihypertensive
treatment. There is no evidence that regimens based on ACE
inhibitors, ARBs, CCBs, or diuretics/beta-blockers are more
effective in one sex than the other.414
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 The efficacy of antihypertensive treatment with regard to
BP reduction and cardiovascular protection is comparable
for men and women. (COR I, LOE B)8.2.1. Effect of oral contraceptives
Oral contraceptives result in a mild increase (~5%) in BP in
most women. The increase in BP usually disappears within 6
months of withdrawal. Estrogens are generally believed to be
the culprit responsible for the BP-raising effect, but the
mechanisms are still unknown. The progestogen-only pill is a
contraceptive option for women having hypertension. Use of
oral contraceptives is associated with a 2- to 6-fold increase in
venous thromboembolic disease and a mild increase in stroke
and myocardial infarction in Western societies. The risk of
cardiovascular complications is observed primarily in women
over 35 years of age and in those who smoke. However, a case-
control study showed that use of oral contraceptives was not
associated with cardiovascular death in Taiwanese women.415
Observational data showed that progestogen-only pills did not
increase the risk of myocardial infarction.416 In summary,
women 35 years of age should be assessed for cardiovascular
risk factors, including hypertension, before taking oral con-
traceptives. In women who smoke and were 35 years of age,
oral contraceptives should be prescribed with caution. In
women with uncontrolled hypertension, oral contraceptives
are not recommended.
Recommendation
 Oral contraceptives should not be used in women with
uncontrolled hypertension. (COR III, LOE C)8.2.2. Effect of hormone replacement therapy
Postmenopausal women taking hormone replacement
therapy may experience a mild increase in SBP over time. A
recent Cochrane systematic review shows that hormone
replacement therapy is associated with a significantly
increased risk of coronary events, stroke, and venous throm-
boembolic disease.417 However, in a retrospective analysis of
Taiwan NHIRD, postmenopausal women treated with hor-
mone replacement therapy (estrogen with or without proges-
terone) for an average of 8 months did not have increased risks
of CHD and stroke with a median follow-up of 110 months.418
A 44% increase in the risk of breast cancer was observed in
women treated with estrogen plus progesterone.418 It is
generally recommended that hormone replacement therapy, as
well as selective estrogen receptor modulators, should not be
used for primary or secondary prevention of cardiovascular
diseases in postmenopausal women.419
Recommendation
 Hormone replacement therapy, as well as selective estro-
gen receptor modulators, should not be used for primary or
secondary prevention of cardiovascular diseases in post-
menopausal women. (COR III, LOE C)8.2.3. Hypertension in pregnancy
In the second trimester, BP normally falls by about
15 mmHg from the pre-pregnancy level. In the third trimester,
BP returns to, or even exceeds, the pre-pregnancy level. The
hypertensive disorders of pregnancy complicate 5 to 10% of
pregnancies. Hypertension during pregnancy is generally
classified into 4 categories: (1) chronic hypertension, (2)
chronic hypertension with superimposed preeclampsia, (3)
preeclampsia-eclampsia, and (4) gestational hypertension.420
The preferred definition of hypertension in pregnancy is
when SBP 140 mmHg or DBP 90 mmHg. Chronic (or
“pre-existing”) hypertension is defined as BP 140/90 mmHg
either before pregnancy or develops before 20 weeks of
gestation. Gestational hypertension generally develops after 20
weeks of gestation and, in most cases, resolves within 6 weeks
postpartum. According to the severity of BP elevation, gesta-
tional hypertension is divided into mild (140/90e149/
99 mmHg), moderate (150/100e159/109 mmHg), and severe
(160/110 mmHg).421 Traditionally, preeclampsia is defined
as gestational hypertension associated with significant pro-
teinuria (>300 mg/24 h, protein/creatinine ratio >0.3 [each
measured as mg/dl] or dipstick 1þ). It is now recognized
that the placenta is the root cause of preeclampsia. Pre-
eclampsia is a multisystem disease, not merely hypertension
and renal dysfunction. The diagnosis of preeclampsia is
therefore not dependent on proteinuria. In the absence of
proteinuria, preeclampsia is diagnosed as hypertension
together with thrombocytopenia (platelet count <100,000/l),
impaired liver function (elevated transaminases >2-fold upper
normal limits), renal insufficiency (serum creatinine >1.1 mg/
dl or doubling of serum creatinine), pulmonary edema, or
cerebral or visual disturbances.420
For women with gestational hypertension with or without
preeclampsia, a normal diet without salt restriction is recom-
mended. Physicians should consider early initiation of anti-
hypertensive treatment to keep BP lower than 150/100 mmHg
but do not lower DBP below 80 mmHg, because decreased BP
in women taking antihypertensive agents is associated with
decreased birth weight. In non-severe hypertension in preg-
nancy (<160/110 mmHg), oral methyldopa, labetalol, and
nifedipine are preferred drugs. Atenolol has been reported to be
associated with fetal growth retardation. ACE inhibitors,
ARBs, direct renin inhibitors, mineralocorticoid receptor an-
tagonists, and chlorothiazide (not other thiazides-like diuretics)
should not be used in pregnancy because of their teratoge-
nicity.420, 421 Diuretic therapy is inappropriate in women with
preeclampsia, which may precipitate volume depletion.
A BP 160/110 mmHg during pregnancy should be
considered an emergency requiring hospitalization. Intrave-
nous labetalol with sequential doses of 20, 40, 80, 80, and
80 mg every 20 minutes, or oral nifedipine (10 mg every 20
minutes up to 5 doses) can be used as first-line treatment.422,
423 Intravenous hydralazine should not be used due to a
higher incidence of perinatal adverse events. Intravenous
nitroglycerin is the drug of choice in preeclampsia with pul-
monary edema. Intravenous sodium nitroprusside is useful in
hypertensive crisis, but prolonged administration should be
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venous magnesium sulfate is effective in the prevention of
eclampsia and the treatment of seizure.
The following antihypertensive drugs do not have adverse
effects on babies receiving breast milk: labetalol, nifedipine,
enalapril, captopril, atenolol, andmetoprolol.421 Daily low-dose
aspirin (60e80mg) is advised for a period of time from12weeks
until the birth of the baby. Low dose aspirin prevents pre-
eclampsia in women with a history of early-onset (<28 weeks)
preeclampsia or preeclampsia in more than one prior preg-
nancy.424 Based on the retrospective analyses of Taiwan
NHIRD, women who have had gestational hypertensive disor-
ders (including preeclampsia) have increased short-term (<1
year) and long-term (up to 9 years) risks of stroke, cardiovas-
cular events, ESRD, and diabetes.425-428 It is generally believed
that preeclampsia does not cause all of these adverse events, but
rather preeclampsia and these adverse events share common risk
factors. For women with preeclampsia and preterm delivery
(<37 weeks of gestation) or recurrent preeclampsia, yearly
assessment ofBP, lipid profile, fasting blood glucose, andBMI is
suggested.
Recommendations
 ACE inhibitors, ARBs, DRI, mineralocorticoid receptor
antagonists, and chlorothiazide are teratogenic. They
should be avoided or immediately withdrawn in case of
pregnancy. (COR III, LOE C)
 For women with gestational hypertension, a normal diet
without salt restriction is recommended. (COR IIa, LOE
C)
 For women with hypertension during pregnancy, early
initiation of antihypertensive treatment to keep BP lower
than 150/100 mmHg and DBP80 mmHg is suggested.
Oral methyldopa, labetalol, and nifedipine are preferred
drugs. (COR IIb, LOE C)
 A BP 160/110 mmHg during pregnancy should be
considered an emergency requiring hospitalization. Intra-
venous labetalol or oral nifedipine can be used as the first-
line treatment. (COR IIa, LOE B)
 In women with a history of early-onset (<28 weeks) pre-
eclampsia or preeclampsia in more than one prior preg-
nancy, low-dose aspirin (60e80 mg/d) for a period of time
from 12 weeks until the birth of the baby is suggested to
prevent preeclampsia. (COR IIb, LOE B)8.3. Perioperative management of hypertensionUntreated hypertension or pre-operative hypertension with
other cardiovascular risk factors increase perioperative
morbidity and mortality.429 Although it is arguable whether
postponing operation is necessary, delay in surgery in patients
with stage 1 or 2 hypertension is not necessary.430, 431 In pa-
tients who have stage 3 hypertension without high cardiovas-
cular risk, an RCT has shown similar clinical outcome between
the postponing operation group and the control group.432
Therefore, routine postponing of operation would not be
necessary in such situations. In these cases, anti-hypertensivedrugs should be continued in perioperative periods. However,
in patients with stage 3 hypertension and high cardiovascular
risk, the potential benefits of delaying surgery to optimize BP
control should be weighed against the risk.430, 431
Use of diuretics should be avoided on the day of surgery
because of potential aggravation of surgery-dependent fluid
depletion.10 There are inconsistent results regarding periop-
erative use of RAS inhibitors. Increased risks with the use of
RAS inhibitors were observed in one RCT433 and 3 observa-
tional studies,434-436 whereas reduced risks were found in 2
observational studies.437, 438 Owing to potential surgery-
related volume depletion, use of RAS inhibitors in the peri-
operative periods should be individualized, based on the fluid
status of patients. Sympathetic overactivity might occur after
withdrawal of some anti-hypertensive drugs, especially
clonidine, beta-blockers, and methyldopa.439-441 Furthermore,
2 observational studies showed that perioperative withdrawal
of beta blockers predicted morbidity and mortality in patients
undergoing vascular surgery.442, 443 Therefore, sudden cessa-
tion of these drugs in perioperative periods should be avoided.
Routine use of beta-blockers in perioperative periods of
non-vascular surgery is still controversial.444-447 In the
DECREASE IV trial of 1066 patients with intermediate car-
diac risk, use of bisoprolol was associated with a significant
reduction of 30-day primary endpoints (cardiac death and
myocardial infarction).444 In the POISE trial of 8351 patients
at risk of atherosclerotic disease, the 30-day primary endpoints
(a composite of cardiovascular death, non-fatal myocardial
infarction, and non-fatal cardiac arrest) were decreased by
metoprolol succinate.446 But total mortality and stroke was
increased.446 Although recent observational studies showed
prognostic benefits of perioperative beta-blockaders in patients
with higher Revised Cardiac Risk Index,448, 449 the most
updated meta-analyses of RCTs have different conclusions.450,
451 In a systemic review for the 2014 ACC/AHA Guidelines on
perioperative cardiovascular evaluation and management,
there were 17 studies included, of which 16 were RCTs.451 It
has been shown that perioperative beta-blockers started within
1 day or less before noncardiac surgery prevented nonfatal
myocardial infarction, but increased the risks of stroke, death,
hypotension, and bradycardia. Without the controversial
DECREASE studies, there are insufficient data on beta-
blockers started 2 or more days prior to surgery. Multicenter
RCTs are needed to address this knowledge gap.451
Clevidipine is a rapid-acting L-type DHP CCB with a ul-
trashort half-life, without reflex tachycardia or tachyphy-
laxis.452-454 The ECLIPSE trial which enrolled 1512
participants undergoing cardiac surgery showed superior BP
reduction with intravenous clevidipine as compared to other
anti-hypertensive drugs, such as sodium nitroprusside, nitro-
glycerin or nicardipine, across all baseline BP subgroups.452
Therefore, clevidipine is preferred in the management of hy-
pertensive crisis during cardiac surgery.
Recommendations
 Delay in surgery in patients with stage 1 or 2 hypertension
is not necessary. (COR IIb, LOE C)
Table 15
Comparison of 2010 hypertension guidelines of TSOC and 2015 hypertension guidelines of TSOC/THS.
2010 TSOC 2015 TSOC/THS
Classification of recommendation  þ
Level of evidence  þ
Standards of IOM  þ
Table for correct BP measurement  þ
BP variability  þ
Diagnostic algorithm  þ
Treatment algorithm þ þ
Adjustment algorithm  þ
Blood pressure targets
<130/80 mmHg Diabetes, CHD and CHD equivalents, CKD, stroke Diabetes, CHD, proteinuric CKD, antithrombotic therapy
<140/90 mmHg Primary prevention, Primary prevention, CKD, stroke
<150/90 mmHg Very elderly (80y) Very elderly (80y)
Life style modification
S-ABCDE þ þ
S Salt restriction <6.0 gm/day Sodium restriction 2.0e4.0 gm/day
Body weight reduction (BMI) 18.5e24.9 kg/m2 22.5e25.0 kg/m2
Exercise adoption (aerobic) 30 minutes/day, at least 5 days/week 40 minutes/day, at least 3e4 days/week
List of recommended drugs þ þ
List of recommended combinations þ 
Figure for “Rule of 10”  þ
Figure for “Rule of 5”  þ
Non-pharmacological therapy  þ
Renal nerve denervation  þ
Perioperative management  þ
BP ¼ blood pressure; CHD ¼ coronary heart disease; CKD ¼ chronic kidney disease; IOM ¼ Institute of Medicine; THS ¼ Taiwan Hypertension Society;
TSOC ¼ Taiwan Society of Cardiology.
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who do not have high cardiovascular risk, is not necessary.
(COR IIa, LOE B)
 In patients with stage 3 hypertension and high cardiovas-
cular risk, the potential benefits of delaying surgery to
optimize BP control should be weighed against the risk.
(COR IIb, LOE C).
 Use of diuretics should be avoided on the day of surgery
because of potential aggravation of surgery-dependent
fluid depletion. (COR IIa, LOE C)
 Use of RAS inhibitors in the perioperative periods should
be individualized, based on fluid status of patients. (COR
IIa, LOE B)
 Sudden cessation of beta-blockers, clonidine, and meth-
yldopa in perioperative periods should be avoided. (COR
III, LOE C)
 Intravenous clevidipine is preferred in the management of
hypertensive crisis during cardiac surgery. (COR IIb,LOEB)
9. Comparison of 2010 Hypertension Guidelines of TSOC
and 2015 Hypertension Guidelines of TSOC/THS
Table 15 shows the similarities and differences of the 2010
hypertension guidelines of TSOC and the 2015 hypertension
guidelines of TSOC/THS. Apparently, the updated 2015
version is more comprehensive. More information and algo-
rithms were provided.
In conclusion the 2015 TSOC/THS hypertension guidelines
provide the most updated information about the management
of hypertension in Taiwan. We emphasized a more aggressiveBP management in certain high risk patients. Useful diagnosis,
treatment, and adjustment algorithms were highlighted. Rec-
ommendations and suggestions regarding S-ABCDE, PRO-
CEED, Rule of 10, Rule of 5, and AT GOALs make it unique
among contemporary hypertension guidelines. We hope the
guidelines can be useful to Taiwanese physicians in helping
their patients in daily practice. We also respect that the phy-
sician's decision remains most important in the management of
hypertension.
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